document incorporate reference portion definitive proxy statement registrant annual meeting shareholder file day conclusion registrant fiscal year end december securities exchange commission pursuant regulation security exchange act amend incorporate reference iii annual report extent describe thereinbristolmyer squibb company index december item business acquisition divestiture product intellectual property product exclusivity research development alliance marketing distribution customer competition pricing price constraint market access government regulation source availability raw material manufacturing quality assurance environmental regulation employee foreign operation bristolmyer squibb website item risk factor item b unresolved staff comment item property item legal proceeding item safety disclosure ia executive officer registrant ii item market registrant common stock stockholder matter item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum consolidate statement earning comprehensive income consolidate balance sheet consolidate statement cash flow note financial statement item change disagreement accountant account financial disclosure item control procedure item b information iii item director executive officer registrant item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction item auditor fee iv item exhibit financial statement schedule item summary signature summary abbreviate term exhibit index indicate brand name product trademark own bms specific trademark ownership information include exhibit index end form kpart item business general bristolmyers squibb company incorporate law state delaware august bristolmyer company successor new york business start bristolmyer company change bristolmyer squibb company result merger engage discovery development licensing manufacturing marketing distribution sale biopharmaceutical product global basis refer summary abbreviate term end term document operate segmentbiopharmaceutical additional information business segment refer item financial statement supplementary datanote accounting policy recently issue accounting standard principal strategy combine resource scale capability pharmaceutical company speed focus innovation biotech industry focus specialty biopharmaceutical company discover develop deliver transformational medicine patient face disease strategic priority drive business performance continue build lead franchise io maintain diversified portfolio outside io continue discipline approach capital allocation include establish partnership collaboration inlicense acquire investigational compound essential component successfully deliver transformational medicine patient expect plan acquisition celgene announce january enable create lead focus specialty biopharmaceutical company position address need patient cancer inflammatory immunologic cardiovascular disease highvalue innovative medicine lead scientific capability plan remain focused broaden portfolio market medicine pipeline asset complementary disease area combine company operate global reach scale speed agility core company strategic approach discussion strategy initiative item management discussion analysis financial condition result operationsstrategy compete worldwide researchbase drug company small research company generic drug manufacturer product sell worldwide primarily wholesaler retail pharmacy hospital government entity medical profession manufacture product puerto rico foreign country revenue come product follow therapeutic class oncology cardiovascular immunoscience percentage revenue significant regioncountry follow year end december dollar millions united states europe rest world total revenue acquisition divestiture license arrangement acquisition divestiture license arrangement allow focus resource growth opportunity drive great longterm value january announce enter definitive merger agreement celgene acquire celgene discussion pende acquisition celgene acquisition divestitures license arrangement refer item risk factor item financial statement supplementary datanote acquisition divestitures license arrangement note subsequent event product intellectual property product exclusivity pharmaceutical product include chemicallysynthesize small molecule drug product produce biological process call biologic small molecule drug typically administer orally eg form pill tablet drug delivery mechanism biologic typically administer patient injection intravenous infusion product summary include approve indication information alliance arrangement product refer alliance item financial statement supplementary datanote alliance opdivo opdivo nivolumab biological product fully human monoclonal antibody bind pd nkt cell opdivo receive approval anticancer indication include bladder blood colon head neck kidney liver lung melanoma stomach opdivoyervoy regimen approve multiple market treatment melanoma rcc crc ongoing potentially registrational study opdivo tumor type disease area monotherapy combination yervoy anticancer agent eliquis eliquis apixaban oral factor xa inhibitor target stroke prevention adult patient nvaf prevention treatment vte disorder orencia orencia abatacept biological product fusion protein indicate adult patient moderately severely active ra psa indicate reduce sign symptom certain pediatric patient moderately severely active polyarticular jia sprycel sprycel dasatinib oral inhibitor multiple tyrosine kinase indicate firstline treatment patient philadelphia chromosomepositive cml chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase cml resistance intolerance prior therapy include gleevec imatinib mesylate treatment child adolescent aged year year chronic phase philadelphia chromosomepositive cml yervoy yervoy ipilimumab biological product monoclonal antibody treatment patient unresectable metastatic melanoma empliciti empliciti elotuzumab biological product humanize monoclonal antibody treatment multiple myeloma baraclude baraclude entecavir oral antiviral agent treatment chronic hepatitis b reyataz franchise reyataz atazanavir sulfate franchise include reyataz protease inhibitor treatment hiv evotaz atazanavir mg cobicistat mg combination therapy contain reyataz tybost cobicistat sustiva franchise sustiva efavirenz franchise nonnucleoside reverse transcriptase inhibitor treatment hiv include sustiva antiretroviral drug bulk efavirenz include combination therapy atripla hepatitis c franchise daklinza daclatasvir nsa replication complex inhibitor sunvepra asunaprevir ns protease inhibitor beclabuvir nsb inhibitor license number patent foreign country primarily cover product develop brand name trademark product consider overall protection patent trademark license intellectual property right material value act protect right infringement pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity product market exclusivity generally determine form intellectual property patent right hold innovator company regulatory form exclusivity innovative drug entitle patent key determinant market exclusivity brand pharmaceutical patent provide innovator right exclude practice invention relate medicine patent cover thing active ingredient use drug product pharmaceutical formulation drug delivery mechanism process intermediate useful manufacture product protection individual product extend vary period accordance expiration date patent country protection afford vary country country depend type patent scope coverage availability meaningful legal remedy country market exclusivity influence rdp exclusivity right develop country provide certain nonpatent incentive development medicine example eu japan certain country rdp exclusivity right offer incentive research medicine rare disease orphan drug medicine useful treat pediatric patient incentive provide market exclusivity period product expire patent term eu japan provide rdp period time approval new drug regulatory agency rely innovators data approve competitor generic copy certain market patent protection form market exclusivity expire rdp particular importance regulatory form exclusivity prevent competitor gain regulatory approval prior expiration rdp exclusivity basis competitor safety efficacy datum drug drug identical market innovator patent right form exclusivity expire generic version medicine approve market substantial rapid decline sale original innovative product discussion impact generic competition business refer competition specific aspect law govern market exclusivity datum regulatory protection pharmaceutical vary country country follow summarize key exclusivity rule market represent significant sale united state key product protect patent vary term depend type patent filing date significant portion product patent life lose time take innovative company develop obtain regulatory approval new drug compensation lose patent term regulatory review period innovator depend number factor apply government restore lose patent term extend expiration date patent maximum term year provide extension cause patent effect year date drug approval company seek market innovative pharmaceutical submit complete set safety efficacy datum fda innovative pharmaceutical chemical product company file nda medicine biological product bla file type application file affect rdp exclusivity right chemical product competitor seek launch generic substitute chemical innovative drug file anda fda anda generic manufacturer need demonstrate bioequivalence generic substitute approve nda drug anda rely safety efficacy datum previously file innovator nda innovator company require list certain patent cover medicine fda commonly know orange book absent successful patent challenge fda approve anda innovators list patent expire innovator market product year generic manufacturer file anda allege patent list orange book innovators nda invalid infringe allegation commonly know paragraph iv certification innovator decide file patent infringement suit generic manufacturer time time anda include paragraph iv certification file respect certain product evaluate andas casebycase basis warrant file suit generic manufacturer protect patent right addition patent protection certain innovative pharmaceutical product receive period regulatory exclusivity nda designate orphan drug receive seven year exclusivity orphan indication time period nda andas drug product approve orphan use company earn month additional exclusivity drug specific clinical study conduct write request fda study use medicine treat pediatric patient submission fda prior loss basic exclusivity medicine approve nda receive type rdp innovative chemical pharmaceutical product entitle year rdp fda approve generic substitute innovators patent challenge describe generic manufacturer file anda fourth year fiveyear rdp period pharmaceutical drug product contain active ingredient previously approve nda approve new formulation drug new indication basis new clinical study receive year rdp formulation indication biologic product healthcare legislation enact create approval pathway biosimilar version innovative biological product previously exist prior time innovative biologic essentially unlimited regulatory exclusivity new regulatory mechanism fda approve product similar generic copy innovative biologic basis extensive datum require bla innovator market product year manufacturer file application approval biosimilar version innovator product application approval biosimilar version file year approval innovator product qualify innovative biological product receive year regulatory exclusivity mean fda approve biosimilar version year innovative biological product approve fda law provide mechanism innovator enforce patent protect innovative biological product biosimilar applicant challenge patent patent litigation begin early year innovative biological product approve fda increase likelihood generic biosimilar challenge innovators intellectual property increase risk loss innovator market exclusivity generic company increasingly seek challenge innovator basic patent cover major pharmaceutical product second statutory regulatory provision limit ability innovator company prevent generic biosimilar drug approve launch patent litigation ongoing result development possible predict length market exclusivity particular product certainty base solely expiration relevant patent current form regulatory exclusivity european union patent pharmaceutical product generally enforceable eu extended compensate patent term lose regulatory review process extension grant countrybycountry basis primary route use obtain marketing authorization pharmaceutical product eu centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum maa ema ema evaluate maa provide recommendation ec ec approve deny maa possible new chemical product obtain marketing authorization eu mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state obtain marketing authorization approval company obtain pricing reimbursement pharmaceutical product typically subject member state law certain eu country process place simultaneously product market eu country process complete company market new product pricing reimbursement procedure month year complete eu product marketing authorization file octobernovember subject regime year innovator receive community authorization medicinal product generic company file maa product health authority maa approved generic company commercialize product year elapse initial marketing authorization grant innovator possible extension year available innovator year marketing authorization obtain additional indication significant clinical benefit comparison exist treatment product file prior octobernovember year period datum protection centralize procedure period year mutual recognition procedure depend member state contrast patent eu list regulatory authority generic version pharmaceutical product approve data protection expire regardless innovator hold patent cover drug possible innovator seek enforce patent generic competitor market product european patent system opposition procedure generic manufacturer challenge validity patent cover innovator product month grant general eu law treat chemicallysynthesize drug biologicallyderive drug respect intellectual property datum protection addition relevant legislation annexe relate biologic medicinal product ema issue guideline outline additional information provide biosimilar product know generic biologic order review application marketing approval japan japan medicines new chemical entity generally afford year datum exclusivity approve indication dosage patent pharmaceutical product enforceable generic copy receive regulatory approval datum exclusivity patent expiration patent japan extended compensate patent term lose regulatory review process general japanese law treat chemicallysynthesize biologicallyderive drug respect intellectual property market exclusivity rest world country outside eu japan wide variety legal system respect intellectual property market exclusivity pharmaceutical develop country utilize system similar eu develop country adopt patent law andor regulatory exclusivity law develop country formally adopt law order comply wto commitment take step implement law meaningful way enforcement wto action long process government assurance outcome assess likely future market exclusivity innovative drug develop country account formal legal right political factor follow chart show key product year early basic exclusivity loss patent right datum exclusivity occur currently estimate occur eu japan sell pharmaceutical product country datum provide country bycountry basis individual country revenue significant outside eu japan instance basic exclusivity loss date list expiration date patent claim active ingredient drug method drug approve indication approve indication instance basic exclusivity loss date list chart expiration date datum exclusivity period situation datum exclusivity patent protection competitor seek regulatory approval submit clinical study datum obtain marketing approval prior expiration datum exclusivity estimate market exclusivity period product purpose business planning length market exclusivity product impossible predict certainty complex interaction patent regulatory form exclusivity inherent uncertainty patent litigation assurance particular product enjoy market exclusivity period time appear estimate exclusivity limited estimate generally estimate loe table pertain rdp composition matter com patent expiration respective product patent term restoration ptr grant estimate loe eua japan prioritize brand opdivo nivolumab eliquis apixaban orencia abatacept b sprycel dasatinib c yervoy ipilimumab empliciti elotuzumab establish brand reyataz atazanavir sulfate franchise expire hepatitis c franchise december epo opposition division uphold validity patent direct use dasatinib treat cml expire refer item financial statement supplementary datanote legal proceeding contingency information eu country grant ptr loe base com patent rdp expiry opdivo eliquis yervoy empliciti b bms aware orencia biosimilar market eu japan eu estimate loe date base method use patent expire formulation additional patent expire c bms enter settlement agreement apotex patent infringement suit cover monohydrate form dasatinib apotex launch generic dasatinib monohydrate anda product september early certain circumstance hepatitis c franchise relate product contain daclatasvir loe date eu reflect pende ptrs research development rd critical longterm competitiveness concentrate rd effort follow disease area significant unmet medical need oncology include io immunoscience priority psoriasis lupus ra inflammatory bowel disease cardiovascular priority heart disease fibrotic disease priority lung ipf liver nash continue analyze selectively pursue promising lead area rd pipeline include potential medicine modality small chemically manufacture molecule large protein moleculesalso know biologicsbut include millamolecule antibody drug conjugate gene therapy addition discover develop new molecular entity look way expand value exist product new indication formulation provide additional benefit patient order new drug reach market industry practice government regulation eu foreign country provide determination drug effectiveness safety preclinical test control clinical evaluation clinical development potential new drug typically include phase phase ii phase iii clinical study design specifically support nda particular indication assume study successful phase clinical study involve small number healthy volunteer patient suffer indicate disease test safety proper dosing phase ii clinical study involve large patient population investigate effect efficacy optimal dosage drug candidate phase iii clinical study conduct confirm phase ii result significantly large patient population long term provide reliable conclusive datum safety efficacy drug candidate regulatory approval typically base result phase iii clinical study times approval grant base datum early study consider registrational study significant rd program program include investigational compound phases ii iii development initial indication market product development additional indication formulation expand currently market product particularly opdivo combination yervoy agent secondline therapy new indication substantial portion rd program strategy drug development time consume expensive risky rd process typically take fourteen year approximately half year spend phase iii latestage development average molecule discover pharmaceutical industry researcher prove medically effective safe approve medicine drug candidate fail stage process latestage product candidate fail receive regulatory approval accord kmr group base industry success rate approximately small molecule enter phase development fail achieve regulatory approval small molecule enter phase ii development failure rate approximately approximately fail phase iii development biologic failure rate approximately phase development approximately phase ii development approximately phase iii development total rd expense include cost discovery research preclinical development earlystage latestage clinical development drug formulation post commercialization medical support market product proportionate allocation enterprisewide cost upfront contingent milestone payment license acquire asset rd expense billion billion billion include license asset acquisition charge approximately billion million end employ approximately people rd relate support activity include substantial number physician scientist hold graduate postgraduate degree higherskille technical personnel manage rd program product portfolio basis invest resource stage rd early discovery latestage development continually evaluate portfolio rd asset ensure appropriate balance earlystage latestage program support future growth company spend latestage development program represent approximately annual rd expense year opdivo individual investigational compound market product represent rd expense year operating model evolution rd geographic footprint significantly transform foster speed innovation future transformation involve closing hopewell new jersey wallingford connecticut rd site accompany additional investment expansion open example expand lawrenceville new jersey redwood city california site open new rd facility cambridge massachusetts supplement internal drug discovery development program alliance collaborative agreement help bring new molecular agent capability platform pipeline management continue emphasize leadership innovation productivity quality strategy success rd activity list investigational compound clinical study approve potential indication market product relate therapeutic area january list compound ultimately market product depend result clinical study competitive landscape potential product market reimbursement decision payer manufacturing process necessary produce potential product commercial scale factor assurance seek regulatory approval compound approval sought obtain assurance compound get approve commercially successful stage development determine intellectual property issue patent protection available investigational compound oncology phase phase ii phase iii approve indication opdivo opdivo opdivo opdivo solid tumor l crc l glioblastoma l braf wildtype metastatic hematologic malignancy nonhodgkin lymphoma diffuse l hcc melanoma opdivo yervoy large bcell lymphoma l head neck adjuvant melanoma solid tumor nonhodgkin lymphoma follicular l head neck locally advanced hodgkin lymphoma relatlimab lymphoma advanced melanoma braf status solid tumor ovarian l esophageal mesothelioma hematologic malignancies pan tumor tmb high adjuvant bladder previously treat advanced nlrp agonist pediatric adjuvant rcc solid tumor primary testicular lymphoma esophagealgastroesophageal previously treat gastric antitim opdivo adjuvant gastric cancer jpn solid tumor solid tumor adjuvant hcc previously treat hcc humaxil opdivo yervoy adjuvant rcc previously treat metastatic head neck solid tumor prostate nsclc neoadjuvant previously treat metastatic ep antagonist opdivo yervoy refractory hodgkin melanoma solid tumor solid tumor lymphoma previously treat metastatic cdcd oncolytic relatlimab opdivo unresectable nsclc msihigh crc virus solid tumor opdivo yervoy previously treat metastatic solid tumor ido opdivo l bladder nonsquamous nsclc antictla probody solid tumor l esophageal previously treat metastatic solid tumor nktr opdivo l gastric squamous nsclc antiicos solid tumor l head neck previously treat metastatic sclc solid tumor ccr dual antagonist l mesothelioma previously treat metastatic antictla nf solid tumor l nsclc urothelial solid tumor cabiralizumab l sclc opdivo yervoy antitigit solid tumor adjuvant melanoma l rcc solid tumor adjuvant rcc braf wildtype metastatic anticd nsclc egfr mutant melanoma solid tumor opdivo yervoy melanoma braf status cabozantinib bet inhibitor previously treat metastatic metastatic rcc solid tumor msihigh crc opdivo empliciti ulocuplumab yervoy multiple myeloma hematologic malignancy adjuvant melanoma opdivo ido adolescent metastatic l metastatic melanoma melanoma neoadjuvant muscleinvasive metastatic melanoma bladder cancer empliciti opdivo nktr relapsedrefractory multiple l melanoma myeloma pomalyst combo l rcc relapsedrefractory multiple relatlimab opdivo myeloma revlimid combo l melanoma sprycel empliciti l cml l multiple myeloma pediatric revlimid combo refractory cml note pipeline exclude clinical collaboration development partnership opdivo yervoy relatlimab ep ono collaboration ono include early stage compound empliciti abbvie nktr nektar cabiralizumab prime cabozantinib exelixis trial explore combination partnerrun study immunoscience phase phase ii phase iii approve indication rort tyk inhibitor orencia orencia autoimmune disease autoimmune disease idiopathic inflammatory early ra sp agonist btk inhibitor myopathy jia intravenous autoimmune disease ra sjgren disease jia subcutaneous btk max tyk inhibitor psoriatic arthritis ra psoriasis ra auto injector tyk inhibitor nulojix ra intravenous switch calcineurin autoimmune disease ra subcutaneous inhibitor renal transplant tlr antagonist nulojix autoimmune disease de novo renal transplant cardiovascular phase phase ii phase iii approve indication fpr agonist nitroxyl donor eliquis eliquis heart failure heart failure pediatric venous stroke prevention atrial fibrillation apj agonist factor xia inhibitor thromboembolism prevention venous thromboembolism prevention orthopedic surgery heart failure thrombosis venous thromboembolism treatment eliquis pediatric heart disease fibrotic disease phase phase ii lpa antagonist hsp fibrosis fibrosis pegbelfermin peg fgf nonalcoholic steatohepatitis note pipeline exclude clinical collaboration development partnership eliquis pfizer factor xia inhibitor janssen hsp nitto denko january follow potential registrational study readout opdivo anticipate tumor study detail tumor study detail cm opdivo yervoy st line cm opdivo chemo st line bladder cancer cm opdivo yervoy st line b cm opdivo adjuvant nonsmall cell lung cm opdivo chemo st line cm opdivo yervoy chemo st line esophageal cancer cancer cmla opdivo yervoy chemo st line cm opdivo adjuvant cm opdivo yervoy egfr tm mutant renal cancer cmer opdivo chemo st line cm opdivo chemo neoadjuvant cm opdivo chemo st line methylate hepatocellular glioblastoma cm opdivo chemo st line unmethylated carcinoma cm opdivo st line cm opdivo yervoy st line mesothelioma cm opdivo yervoy st line head neck cancer cm opdivo yervoy st line melanoma cm opdivo yervoy adjuvant phase ii phase iii alliance enter alliance party transfer right develop manufacture market andor sell pharmaceutical product alliance include license codevelopment cocommercial arrangement joint venture alliance involve share research development cost overall investment risk bms compound lead revenuegenerate product reduce profitability alliance product generally low profit alliance product share alliance partner profit sharing royalty actively pursue arrangement view alliance important complement discovery development commercialization activity alliance arrangement contain customary early termination provision follow material breach bankruptcy product safety concern arrangement typically provide termination bms cause notice require early termination generally range immediately notice day receipt notice termination immediately notice generally available party file voluntary bankruptcy petition material safety issue arise product medical riskbenefit incompatible welfare patient continue develop commercialize product termination notice period generally available involuntary bankruptcy petition file dismiss material breach party occur cure bms terminate cause bms right terminate cause exercisable specify period time elapse alliance agreement sign alliance typically contain provision provide party right terminate alliance typically retain right party product intellectual property alliance terminate loss right product market sell pursuant alliance material result operation loss cash flow cause loss right material financial condition liquidity alliance agreement structure terminate specific date product patent expiration date expiry date profit sharing payment typically expiration date royalty payment cease loe include patent expiration refer item financial statement supplementary datanote alliance information significant alliance agreement alliance agreement marketing distribution customer promote appropriate use product directly healthcare professional organization doctor nurse practitioner physician assistant pharmacist technologist hospital pbms mco provide information appropriate use product consumer directtoconsumer print radio television digital advertising promotion addition sponsor general advertising educate public innovative medical research corporate mission discussion regulation promotion marketing pharmaceutical refer government regulation field sale medical organization explain risk benefit approve use product medical professional work gain access product formulary reimbursement plan list recommend approve medicine product include medicare plan provide information clinical profile product marketing sale prescription pharmaceutical limit approve use particular product continue develop scientific datum information potential additional use product provide information scientific exchange scientific congress share information product appropriate way include development publication response unsolicited inquiry doctor medical professional mcos operation include marketing sale organization product marketing organization support sale force responsible sell product market organization focus certain class customer manage care entity certain type marketing tool digital consumer communication sale force focus communicate information new approve product use approve use establish product promotion physician increasingly target physician specialist treat patient need medicine product sell principally wholesaler specialty distributor less extent directly distributor retailer hospital clinic government agency pharmacy refer item financial statement supplementary datanote revenue gross revenue large pharmaceutical wholesaler percentage global gross revenue business dsas substantially direct wholesaler distributor customer allow monitor wholesaler distributor inventory level require wholesaler distributor maintain inventory level month demand dsa include large wholesaler expire december subject certain termination provision nonus business significantly direct customer information available direct customer product level inventory correspond movement information reliability thirdparty demand information vary widely limit direct customer sale channel inventory report reliably gather report inventory level customer number country outside contract distributor support certain product service provide distributor vary market include distribution logistic regulatory pharmacovigilance andor sale advertising promotion sale distributorbase country represent approximately company total revenue competition market compete generally broad base highly competitive compete worldwide researchbase drug company small research company limit therapeutic focus generic drug manufacturer important competitive factor include product efficacy safety ease use price demonstrate costeffectiveness marketing effectiveness product label customer service rd new product process sale product impact new study indicate competitor product safe effective treat disease particular form disease product revenue impact additional labeling requirement relate safety convenience impose product fda similar regulatory agency different country competitor introduce new product process therapeutic cost advantage product subject progressive price reduction decrease volume sale advancement treat cancer io therapy continue evolve rapid pace io product particularly opdivo operate highly competitive marketplace addition compete market share io product approve indication lung cancer melanoma face increase competition exist compete io product receive fda approval additional indication new io agent receive fda approval enter market furthermore therapy combine different io product io product exist chemotherapy target therapy treatment investigate potential expand approval anticipate io product continue experience intense competition competitive challenge face generic pharmaceutical manufacturer eu regulatory approval process exempt generic costly timeconsuming clinical study demonstrate safety efficacy allow generic manufacturer rely safety efficacy innovator product result generic pharmaceutical manufacturer typically invest far rd researchbase pharmaceutical company price product significantly lower brand product accordingly brand product lose market exclusivity normally face intense price competition generic form product expiration loss market exclusivity product lose major portion product revenue short period time expiration exclusivity rate revenue decline product vary country general decline market rapid develop country observe rapid decline number eu country decline develop country tend rapid develop country rate revenue decline expiration exclusivity historically influence product characteristic example drug large patient population eg prescribed key primary care physician tend experience rapid decline drug specialized area medicine eg oncology drug complex manufacture eg sterile injectable product usually experience slow decline simple manufacture certain country outside patent protection weak nonexistent compete generic version shortly launch innovative product addition generic pharmaceutical company introduce generic product exclusivity expire resolution relate patent litigation information market exclusivity refer product intellectual property product exclusivity believe longterm competitive position depend success discover develop innovative costeffective product serve unmet medical need ability manufacture product efficiently market effectively highly competitive environment pricing price constraint market access medicine price base number factor include value scientific innovation patient society context overall health care spend economic factor impact health care system ability provide appropriate sustainable access necessity sustain investment innovation platform address unmet medical need central price clinical value innovation bring market current landscape alternative treatment option goal ensure appropriate patient access innovation sustain investment creative platform continue explore new pricing approach ensure patient access medicine enhance patient access medicine priority focus offer creative tiere pricing voluntary licensing reimbursement support patient assistance program optimize access protect innovation advocate sustainable healthcare policy infrastructure leverage advocacypayer input utilize partnership appropriate improve access care supportive service vulnerable patient partnership demonstration project important factor pricing medicine depend government regulation subject increase international domestic effort government implement strengthen measure regulate pharmaceutical market access product pricing payment operate globally country robust governmentmandate cost containment program effort control cost manage use product remain strong certain market outside require provide discount pricing rebate federal government respective state government purchase pharmaceutical product federal state healthcare program federal government official legislator continue face intense pressure public manage perceive high cost pharmaceutical respond pursue legislation rule reduce cost drug federal government pays monitor effort state include law recently enact california vermont nevada new york focus provide drug pricing transparency seek additional rebate limit state spend drug international federal state legislative regulatory development create new constraint ability set price andor impact market access certain area discussion pricing pressure risk refer item risk factor growth mcos optum uhc silver script cvs express script esi major factor healthcare marketplace half population participate version manage care mco include medical insurance company medical plan administrator health maintenance organization medicare prescription drug plan alliance hospital physician physician organization organization consolidate few large entity enhance purchasing strength importance successfully compete business mcos demonstrate product offer medical benefit cost advantage compare form care new product introduce compete product market product later develop competitor note generic drug exempt costly timeconsuming clinical study demonstrate safety efficacy lower cost brandname drug mcos focus primarily immediate cost drug favor generic reason government encourage use generic alternative brandname drug healthcare program law generally allow case require pharmacist substitute generic drug rate government procedure essentially equivalent brandname drug substitution prescribe physician expressly forbid exclusion product formulary lead sharply reduce usage mco patient population consequently pharmaceutical company compete aggressively product include possible company compete inclusion base unique feature product great efficacy well patient ease use few effect low overall cost therapy important factor product demonstrate few therapeutic advantage compete inclusion base primarily price generally universally successful major product include mco formulary market outside operate environment governmentmandate costcontainment program market significant portion fund healthcare service determination pricing reimbursement pharmaceutical product subject direct government control point care government significant power large single payer result product face restrict access public private payer subject assessment comparative value effectiveness competitive product government place restriction physician prescription level patient reimbursement emphasize great use generic drug andor enact acrosstheboard price cut rebate scheme method cost control eu countries example government regulate price new product launch direct price control international price comparison control profit andor reference pricing eu markets germany government set pricing restriction launch pricing freedom subsequently limit company face significant delay market access new product mainly france spain italy belgium year elapse new medicine available patient market additionally member states eu regularly impose new additional cost containment measure pharmaceutical volume discount cost cap cost sharing increase excess prior year cost individual product aggregate market level spend outcomebase pricing scheme free product portion expect therapy period recent year italy example impose mandatory price decrease clawback rebate structure existence price differential eu different national pricing reimbursement law lead significant parallel trade flow government regulation pharmaceutical industry subject extensive global regulation regional country state local agency federal food drug cosmetic act federal statute regulation state statute regulation include newly enact state law regulate drug price transparency rebate drug spending law regulation foreign government govern vary degree test approval production labeling distribution postmarket surveillance advertising dissemination information promotion product lengthy process laboratory clinical testing datum analysis manufacture development regulatory review necessary require governmental approval extremely costly significantly delay product introduction give market promotion marketing manufacturing distribution pharmaceutical product extensively regulate major world market addition operation subject complex federal state local foreign environmental occupational safety law regulation anticipate law regulation affect manufacture sale current product introduction new product continue require substantial scientific technical effort time expense significant capital investment fda particular importance jurisdiction virtually activity impose requirement cover testing safety effectiveness manufacturing labeling marketing advertising postmarkete surveillance product case fda requirement increase time money necessary develop new product bring market regulatory review process resource intensive undertake fda pharmaceutical manufacturer improvement efficiency process significant impact bring new therapy patient quickly fda employ tool expedite certain application include fast track designation accelerate approval recently fda oncology center excellence oce establish new pilot project test novel approach regulatory review oncology drug realtime oncology review rtor assessment aid aaid aaid pilot program fda approve empliciti november additional multiple myeloma indication combination pomalidomide dexamethasone treatment adult patient receive prior therapy include lenalidomide proteasome inhibitor approval achieve week priority review prescription drug user fee act pdufa date fda mandate drug manufacture package label conformity cgmp establish fda comply cgmp regulation manufacturer continue expend time money effort production recordkeeping quality control ensure product meet applicable specification requirement ensure product safety efficacy fda periodically inspect drug manufacturing facility ensure compliance applicable cgmp requirement failure comply statutory regulatory requirement subject possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experience use product report fda result imposition market restriction label change product removal product approval withdraw compliance regulatory requirement maintain problem concern safety efficacy occur follow approval federal government extensive enforcement power activitie pharmaceutical manufacturer include authority withdraw delay product approval commence action seize prohibit sale unapproved noncomplye product halt manufacture operation compliance cgmp impose seek injunction voluntary recall civil monetary criminal penalty restriction prohibition sale withdrawal approval product market materially adversely affect business financial condition result operation cash flow marketing authorization product subject revocation applicable governmental agency addition modification enhancement approve product change manufacturing location circumstance subject additional fda approval receive subject lengthy application process distribution pharmaceutical product subject pdma federal food drug cosmetic act regulate activity federal state level pdma implement regulation state permit require registration manufacturer distributor provide pharmaceutical manufacturer distributor place business state state permit adopt regulation limit distribution product sample license practitioner pdma impose extensive licensing personnel recordkeeping packaging quantity labeling product handle facility storage security requirement intend prevent sale pharmaceutical product sample product diversion fda amendment act impose additional obligation pharmaceutical company delegate enforcement authority fda area drug safety key element legislation fda authority require company conduct postmarkete safety study drug impose certain safety relate drug labeling change mandate risk mitigation measure education healthcare provider restrict distribution medicine require company publicly disclose datum clinical study prereview television advertisement marketing practice pharmaceutical manufacturer subject federal state healthcare law protect integrity government healthcare program oig oversee compliance applicable federal law connection payment product government fund program primarily medicaid medicare law include federal antikickback statute criminalize offer value induce recommendation order purchase product service reimburse government healthcare program oig issue series guidance segment healthcare industry include compliance program guidance pharmaceutical manufacturer include recommendation pharmaceutical manufacturer minimum adhere phrma code voluntary industry code marketing practice subscribe phrma code implement compliance program address requirement set forth guidance compliance healthcare law failure comply healthcare law subject administrative legal proceeding include action federal state government agency action result imposition civil criminal sanction include fine penalty injunctive remedy impact materially adversely affect business financial condition result operation cash flow subject jurisdiction federal state regulatory enforcement department agency federal trade commission department justice department health human service license drug enforcement administration procure produce control substance subject possible administrative legal proceeding action organization action result imposition civil criminal sanction include fine penalty injunctive administrative remedy healthcare industry subject governmentimposed regulation authorize price price control continue impact total revenue participate state government medicaid program certain qualify federal state government program discount rebate provide participate state local government entity participate government program specify discount certain government entity significant department defense department veterans affair entity receive minimum discount base define nonfederal average manufacturer price purchase result hr reconciliation bill contain package change healthcare bill continue experience additional financial cost certain change business example minimum rebate medicaid drug sale increase medicaid rebate extend drug riskbase medicaid manage care plan addition extend discount certain critical access hospital cancer hospital cover entity require expansion b drug pricing program public health service act require provide discount rise brandname drug patient fall medicare coverage gap refer donut hole pay annual nontaxdeductible fee federal government base allocation market share brand drug sale certain government program include medicare medicaid department veterans affairs department defense tricare annual fee impose pharmaceutical manufacturer billion billion fee decrease billion activity outside subject regulatory requirement govern testing approval safety effectiveness manufacturing labeling marketing product regulatory requirement vary country country fda ec approval obtain product approval product comparable regulatory authority country outside eu case obtain prior marketing product country approval process rigorous country country time require approval long shorter require approval country assure product approve country discussion rebate program refer item management discussion analysis financial condition result operation gtn adjustment critical accounting policy source availability raw material general purchase raw material supply require production product open market product purchase raw material supply source source available single source approve source available require obtain raw material supply particular source attempt possible mitigate raw material supply risk inventory management alternative source strategy discussion source refer manufacture quality assurance discussion particular product manufacture quality assurance operate manage manufacturing network manner permit improve efficiency maintain flexibility reallocate manufacturing capacity pharmaceutical production process complex highly regulate vary widely product product give shift add manufacturing capacity lengthy process require significant capital expenditure regulatory approval maintain operate flexible manufacturing network consist internal external resource minimize unnecessary product transfer inefficient use manufacturing capacity discussion regulatory impact manufacturing refer government regulation significant pharmaceutical manufacturing facility locate puerto rico ireland france italy require significant ongoing capital investment maintenance compliance increase regulatory requirement addition product portfolio continue evolve expect continue modification exist manufacturing network meet complex processing standard require newly introduce product include biologic biologic manufacturing involve complex process traditional pharmaceutical operation fda approve large scale multi product bulk biologic manufacturing facility deven massachusetts continue capital investment facility startup phase new largescale biologic manufacturing facility cruiserath ireland expect approve commercial use early rely party manufacture supply portion active product ingredient drug substance necessary manufacture product opdivo eliquis orencia sprycel yervoy baraclude reyataz sustiva franchise continue shift thirdparty manufacturer supply establish brand maintain stable supply product variety action include inventory management maintenance additional quantity material possible design provide reasonable level ingredient hold thirdparty supplier manufacturing operation interrupt certain supply arrangement extend multiple year commit amount expect near longterm demand requirement subject change additional protection case step maintain approve source available example capability manufacture opdivo internally arrangement thirdparty manufacturer meet demand connection acquisition divestiture license collaboration arrangement distribution agreement certain product certain circumstance enter agreement agree supply product party intend continue enter agreement future addition liability arise failure supply product agreement arrangement require invest facility production nonstrategic product result additional regulatory filing obligation cause interruption manufacturing product success depend great measure customer confidence quality product integrity datum support safety effectiveness product quality arise total commitment quality part operation include research development purchasing facility planning manufacturing distribution maintain record demonstrate quality integrity technical information production process control production process involves establish specification standard ingredient equipment facility manufacturing method operation packaging material labeling perform test stage production process final product product sample hold stability ensure product meet regulatory requirement conform standard test involve chemical physical analyse microbiological testing combination analyse quality control testing provide business unitsite thirdparty laboratory quality assurance group routinely monitor manufacturing procedure system subsidiary thirdparty supplier assure quality compliance requirement meet environmental regulation facility operation subject extensive foreign law regulation relate environmental protection human health safety include govern discharge pollutant air water use management disposal hazardous radioactive biological material waste cleanup contamination pollution control permit require operation permit subject modification renewal revocation issue authority environment health safety group monitor operation world provide overview regulatory requirement oversee implementation standard compliance incur operating capital cost matter ongoing basis material addition invest project reduce resource use energy water believe substantial compliance applicable environmental health safety requirement permit require operation incur additional cost include civil criminal fine penalty cleanup cost thirdparty claim property damage personal injury violation liabilitie law current facility operation year time operator facility generate store dispose substance waste consider hazardous federal state andor foreign environmental law include cercla result soil groundwater certain facility contaminate require significant expenditure investigate control remediate contamination case provide compensation andor restoration damage natural resource currently involve investigation remediation current facility identify prp applicable law environmental condition approximately waste disposal reprocess facility operate party investigation andor remediation activity ongoing face liability cercla federal state foreign law entire cost investigation remediation contaminate site natural resource damage regardless fault ownership time disposal release addition certain site bear remediation responsibility pursuant contractual obligation generally thirdparty operator site involve multiple prps liability expect apportion base nature hazardous substance dispose party site number financially viable prps additional information matter refer item financial statement supplementary datanote legal proceeding contingency employee approximately employee december foreign operation significant operation outside conduct subsidiary distributor international operation subject certain risk inherent conduct business abroad include limited currency fluctuation possible nationalization expropriation price exchange control counterfeit product limitation foreign participation local enterprise restrictive governmental action international business subject governmentimpose constraint include law price reimbursement use product bristolmyer squibb website internet website address wwwbmscom website available free charge annual quarterly current report include amendment report soon reasonably practicable electronically file material furnish material sec pursuant section securities exchange act amended exchange act document available secs website wwwsecgov information relate corporate governance bristolmyer squibb include principle integrity code ethic senior financial officer code business conduct ethic director collectively code corporate governance guideline information concern executive committee board director include board committee committee charter transaction bristolmyers squibb security director executive officer available website usour company leadership investor caption print stockholder request waiver code director executive officer material amendment code business conduct ethic director code ethic senior financial officer post promptly website information relate stockholder service include dividend reinvestment plan direct deposit dividend available website investorsshareholder service caption addition information sustainability program available website ussustainability caption forego information website content convenience information contain connected website deem incorporate reference file sec incorporate reference certain information part definitive proxy statement annual meeting shareholder proxy statement sec allow disclose important information refer manner refer information proxy statement available website investorssec filing caption day end fiscal year item risk factor risk uncertainty describe significantly negatively affect business prospect financial condition operating result credit rating cause trading price common stock decline additional risk uncertainty presently know risk currently consider immaterial impair business operation financial condition follow discussion risk factor contain forwardlooke statement discuss item management discussion analysis financial condition result operationsspecial note forwardlooke statement face certain risk connection propose acquisition celgene describe item encourage consider risk caption risk relate propose acquisition celgene risk factor set forth registration statement form registration initially file sec february subsequently amend february february additional risk factor relate proposed acquisition celgene risk relate business public announcement datum clinical study competitor news development relate competitor product latestage compound cause significant volatility stock price depend datum result adverse impact business financial condition result operation development key io compound combination therapy delay discontinued clinical study meet primary endpoint stock price decline significantly adverse impact business financial condition result operation focus effort resource disease area high unmet need focus portfolio investor place heighten scrutiny product latestage compound particular opdivo backbone io portfolio announce multiple regulatory milestone opdivo result label expansion new indication experience setback continue development clinical study expect receive datum ongoing clinical study include information checkmate combination study firstline lung cancer setting decision health authority potential label expansion announcement datum clinical study competitor news development relate competitor product late stage compound opdivo cause significant volatility stock price depend news result adverse impact business financial condition result operation furthermore announcement negative unexpected datum discontinuation development key io compound combination therapy delay anticipate timeline file regulatory approval significant advancement competitor cause stock price decline significantly adverse impact business financial condition result operation assurance datum clinical study support filing regulatory approval key io compound prove effective effective compete compound approve key io compound commercially successful approve indication depend key product revenue cash flow earning derive majority revenue earning key product prioritize brand comprise approximately revenue growth product opdivo eliquis represent expected increasingly represent significant revenue earning cash flow reduction revenue product adversely impact earning cash flow major product subject issue loss patent protection significant change demand formulary access change material product liability unexpected effect regulatory proceeding negative publicity supply disruption manufacturing operation thirdparty supplier significant advancement compete product incur adverse impact business financial condition result operation trading price stock experience difficulty delay development commercialization new product compound product appear promise development fail reach market expected optimal timeframe addition product extension additional indication approve furthermore product indication approve fda accelerated approval program contingent verification description clinical benefit confirmatory study study successful example november announce checkmate study meet primary endpoint overall survival opdivoyervoy versus placebo maintenance therapy patient extensivestage sclc completion firstline platinumbase chemotherapy develop commercialize new compound product include inherent risk uncertainty include efficacy safety concern delay deny regulatory approval delay challenge produce product commercial scale excessive cost manufacture ii failure enter implement optimal alliance development andor commercialization new product iii failure maintain consistent scope variety promise latestage product iv failure product achieve maintain commercial viability v change regulatory approval process cause delay denial new product approval regulatory approval delay especially common product expect risk evaluation mitigation strategy require fda address significant riskbenefit issue inability bring product market significant delay expect approval relate launch date new product negatively impact revenue earning addition certain acquire pipeline program cancel believe commercial prospect reduce recognize material noncash impairment charge program finally lose key molecule intermediary compound library natural manmade disaster act sabotage negatively impact product development cycle face intense competition manufacturer bms dependent market access uptake expansion market brand new product introduction new indication product extension co promotional activity alliance partner deliver future growth competition keen include lowerprice generic increasingly aggressive generic commercialization tactic ii new competitive product enter market particularly io iii low price company product real perceive superior efficacy benefit safety risk profile differentiate factor iv technological advance patent attain competitor v clinical study result product competitor product affect value proposition product vi business combination competitor major thirdparty payer vii compete interest external partnership develop bring new product market unable compete successfully competitor product marketplace material negative impact revenue earning lose market exclusivity product early expect pharmaceutical biotechnology industry majority innovative product commercial value realize market exclusivity period country market exclusivity expire generic version approve market biosimilar introduce compete product usually substantial rapid decline product revenue market exclusivity product base patent right certain regulatory form exclusivity scope patent right vary country country dependent availability meaningful legal remedy country failure obtain patent intellectual property right limitation use loss right material country include certain eu member state basic patent protection product exist certain country historically offer right obtain specific type patent andor licensor file country addition patent environment unpredictable validity enforceability patent predict certainty absent relevant patent protection product datum exclusivity period expire generic version approve market generic biosimilar product manufacturer group seek financial gain increasingly seek challenge patent expire face earlierthanexpecte competition product time patent cover key product likely continue subject patent litigation example february eu patent sprycel revoke opposition division epo experience decline european revenue entry generic market refer item financial statement supplementary datanote legal proceeding contingency information case manufacturer seek regulatory approval submit clinical study datum obtain marketing approval choose launch generic product risk expiration applicable patent andor final resolution relate patent litigation assurance particular product enjoy market exclusivity time period appear estimate disclose assume provide financial guidance addition country india allow competitor manufacture sell compete generic product negatively impact protection afford company lowerprice biosimilar bms biologic product compete biologic negatively impact volume price litigation claim infringement intellectual property adversely affect future revenue operate earning party claim infringe intellectual property resolve intellectual property infringement claim costly time consuming require enter license agreement available commercially reasonable term successful claim patent intellectual property infringement subject significant damage injunction prevent manufacture sale use affect product product event material adverse effect profitability financial condition addition propose celgene acquisition consummate subject certain intellectual property claim celgene adverse outcome legal matter negatively affect business current future lawsuit claim proceeding government investigation preclude delay commercialization product adversely affect operation profitability liquidity financial condition possible insurance recovery available legal matter include intellectual property dispute ii adverse decision litigation include product liability commercial case iii antibribery regulation foreign corrupt practice act uk bribery act include compliance ongoe reporting obligation government result settlement iv recall withdrawal pharmaceutical product force closing manufacture plant v failure fulfill obligation supply contract government customer vi product pricing promotional matter vii lawsuit claim assert investigation violation security antitrust federal state pricing consumer protection datum privacy law viii environmental health safety sustainability matter ix tax liability result assessment tax authority increase pricing pressure restriction abroad mcos institutional purchaser government agency program negatively affect revenue profit margin product continue subject increase pressure portfolio market access pricing discount restriction eu region world include rule practice mcos institutional governmental purchasers ii government administrative policy change change law regulation federal healthcare program medicare medicaid government action inquirie federal level include proposal contain american patient blueprint seek amend pharmaceutical pricing rebate reimbursement practice international pricing index modify federal antikickback statute discount safe harbor accelerate generic drug approval process promote use biosimilar drug option apply step therapy list price product advertising grant additional authority governmental agency manage drug utilization negotiate drug price law state level recently enact california vermont nevada new york focus drug pricing transparency andor limit state spend drug iii potential impact change pharmaceutical reimbursement change result implementation guidance final rule issue center medicare medicaid services cms calculation average manufacturer price good price change require base guidance cms rule defer iv impact increase pricing pressure medicare formulary medicare b reimbursement rate physician expand utilization b drug pricing program commercial formulary general v reimbursement delay vi government price erosion mechanism europe country result deflation pharmaceutical product pricing vii collection delay failure pay governmentfunde public hospital outside viii impact pricing parallel trade drug importation border ix development technology andor industry practice impact reimbursement policy practice party payer x inhibited market access real perceive difference value proposition product compare compete product subject variety international law regulation currently subject number government law regulation future subject new government law regulation cost compliance law regulation negative result noncompliance adversely affect business operating result financial condition company include additional healthcare reform initiative country include additional mandatory discount fee ii new law regulation judicial governmental decision affect pricing drug reimbursement receivable payment access marketing jurisdiction iii change intellectual property law iv change accounting standard v new increase datum privacy regulation enforcement particularly eu vi emerge new global regulatory requirement report payment value transfer healthcare professional vii potential impact importation restriction legislative andor regulatory change change tax regulation negatively impact earning subject income taxis country globally particular passage tax cut job act reduce tax rate future earning negatively impact change tax legislation include change tax rate tax base limit phasingout eliminate deduction tax credit tax certain excess income intellectual property change rule earning repatriation change tax law country thirdparty royalty represent significant percentage pretax income operate cash flow enter arrangement entitle potential royalty party outlicense intellectual property commercialization right salesbase contingent proceed relate divestiture business arrangement minimal continue involvement contribute financial success activity royalty continue represent significant percentage pretax income include royalty relate divestiture plavix avaproavalide erbitux diabetes business include transfer certain future royalty right pertain amylin onglyza farxiga product sale sanofi arrangement outlicense intellectual property merck patent infringement settlement pretax income generate royalty approximately billion pretax income adversely affect royalty stream decline future period failure party meet contractual regulatory obligation adversely affect business rely supplier vendor outsource partner alliance partner party research develop manufacture commercialize copromote sell product manage certain marketing sell human resource finance business unit functional service meet contractual regulatory obligation party pose number risk perform standard legal requirement example relation outsource significant clinical development activity innovative medicine contract research organization ii produce reliable result iii perform timely manner iv maintain confidentiality proprietary information v incur significant cyberattack business disruption vi dispute arise respect ownership right technology develop partner vii disagreement cause delay termination research development commercialization product result litigation arbitration party locate market subject political social risk corruption infrastructure problem natural disaster addition country specific privacy datum security risk give current legal regulatory environment failure critical party meet obligation include future royalty milestone payment adequately deploy business continuity plan event crisis andor satisfactorily resolve significant disagreement address factor material adverse impact operation result addition party violate allege violate law regulation include local pharmaceutical code foreign corrupt practice act uk bribery act similar law regulation performance obligation possible suffer financial reputational harm negative outcome include possible legal consequence failure execute business strategy adversely impact growth profitability strategy focus deliver innovative transformational medicine patient focus set disease area unable successfully execute strategy negatively impact future result operation market capitalization connection strategy process acquire celgene lead innovative biotech company complement exist portfolio medicine pipeline asset key disease area focus ability successfully complete acquisition successfully integrate celgene impact result operation able achieve cost saving expect negatively impact operate margin earning result addition unable consistently maintain adequate pipeline internal rd program transaction party support future revenue growth competition pharmaceutical company acquisition product licensing opportunity intense able locate suitable acquisition target license partner reasonable price successfully execute transaction unable support grow market product successfully execute launch newly approve product advance latestage pipeline manage change operating model evolution manage cost effectively operate result financial condition negatively impact failure attract retain highly qualified personnel affect ability successfully develop commercialize product success largely dependent continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical rd governmental regulation commercialization competition qualified personnel biopharmaceutical field intense sure able attract retain quality personnel cost materially increase business asset acquire future underperform able successfully integrate exist business occurrence number unexpected factor prevent substantially delay consummation anticipate acquisition divestiture merger acquire inlicense number asset expect continue support pipeline compound product obtain licensing acquisition future revenue profit cash flow acquire company product technology pipeline candidate materialize low product uptake delay miss pipeline opportunity inability capture expect synergy increase competition safety concern regulatory issue supply chain problem factor control substantial difficulty cost delay result integrate acquisition include rd manufacturing distribution sale marketing promotion information technology activity ii policy procedure process control compliance iii tax consideration addition substantial debt expect incur finance cash portion propose celgene acquisition consideration assurance acquisition consummate choose continue invest technology experience difficulty delay manufacture distribution sale product product supply relate patient access negatively impact thing product seizure recall force closing manufacture plant ii failure failure supplier comply cgmp applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture iii manufacturing quality assurancequality control supply problem governmental approval delay iv failure sole source single source supplier provide necessary raw material supply finish good reasonable timeframe require quality v failure thirdparty manufacturer supply bulk active finished product time vi construction regulatory approval delay new facility expansion exist facility include intended support future demand biologic product opdivo vii failure meet new emerge regulation require product track distribution channel unique identifier verify authenticity supply chain viii manufacturing distribution issue include limit manufacturing capacity change type product produce biologic physical limitation business interruption ix disruption supply chain continuity include natural disaster act war terrorism external factor control impact facility critical supplier example new biologic manufacturing facility cruiserath ireland expect approve commercial use early delay plan opening site impact supply product require obtain product supply party significant cost product labeling change market product result negative impact revenue profit margin regulatory authority need change label pharmaceutical product include product market year change result additional datum postmarkete study headtohead study adverse event report study identify biomarker objective characteristic indicate particular response product therapy study postmarkete experience produce important additional information product new information add product label affect riskbenefit profile lead potential recall withdrawal decline revenue product liability claim additional information study identify portion patient population nonresponsive medicine high risk adverse reaction label change base study limit patient population study provide additional information sponsor sponsor competitor insurance company government institution mcos scientist investigator interested party additional safety efficacy information study assist healthcare provider identify good patient population product negatively impact revenue inventory return limit patient population go forward additionally certain study result especially headtohead study affect product formulary listing adversely affect revenue illegal distribution sale party counterfeit unregistered version product steal product negative impact revenue earning reputation business party illegally distribute sell counterfeit version product meet rigorous manufacturing testing standard patient receive counterfeit drug risk number dangerous health consequence reputation business suffer harm result counterfeit drug sell brand theft inventory warehouse plant intransit properly store later sell unauthorized channel adversely impact patient safety reputation business addition diversion product authorize market channel result reduced revenue negatively affect profitability dependent information technology system infrastructure face certain risk include cybersecurity breach datum leakage rely extensively system network service include internet site data host processing facility tool physical security system hardware software technical application platform manage host provide andor thirdpartie vendor assist conduct business significant breakdown invasion corruption destruction interruption critical information technology system infrastructure workforce authorize access system unauthorized person negatively impact operation everincrease use evolution technology include cloudbase computing create opportunity unintentional dissemination intentional destruction confidential information store thirdparty provider system portable medium storage device experience business interruption theft confidential information reputational damage industrial espionage attack malware cyberattack compromise system infrastructure lead datum leakage internally thirdparty provider aggregate impact operation financial condition material date target event nature expect continue cybersecurity threat rapidly evolve sophistication prevalent industry invest industry appropriate protection monitor practice datum reduce risk continue monitor system ongoing basis current potential threat maintain cyber insurance insurance sufficient cover financial legal business reputational loss result interruption breach system assurance continue effort prevent breakdown breach thirdparty provider database system adversely affect business adverse change global economic political condition adversely affect profitability global economic political risk pose significant challenge company growth profitability difficult mitigate generate approximately revenue outside revenue earning cash flow expose risk strengthen dollar exposure customer credit risk europe south america market include governmentguaranteed hospital receivables market payment receive time significant operation europe include manufacture distribution result operation negatively impact member country exit eurozone monetary union eu include planned exit uk eu particular exit withdrawal agreement associate transition period place impact research commercial general business operation uk eu include approval supply product addition discontinuation modification libor future initiative regulate reform change manner administration benchmark result adverse consequence return value market security instrument return link benchmark additionally future pension plan funding requirement continue sensitive global economic condition relate impact equity market disruption credit market downgrade current credit rating increase future borrowing cost impair ability access capital credit market term commercially acceptable adversely affect liquidity capital resource significantly increase cost capital finally business operation adversely affect political volatility conflict crise individual country region include terrorist activity war guarantee pay dividend repurchase stock declaration time dividend fall discretion board director board decision depend factor include financial condition earning capital requirement debt service obligation industry practice legal requirement regulatory constraint factor board deem relevant reduction elimination dividend payment dividend program adversely affect stock price addition time decide buy share market adversely affect stock price increase use social medium platform present risk challenge increase use social medium communicate company news event inappropriate andor unauthorized use certain medium vehicle cause brand damage information leakage lead legal implication include improper collection andor dissemination personally identifiable information employee patient healthcare professional stakeholder addition negative inaccurate post comment social network website damage reputation brand image goodwill disclosure nonpublic companysensitive information workforce external medium channel lead information loss identify new point entry social medium continue expand present new challenge risk relate propose acquisition celgene realize anticipate benefit synergy propose acquisition celgene january announce enter definitive merger agreement celgene acquire celgene celgene continue operate independently completion acquisition success acquisition depend ability realize anticipate benefit successfully combine celgene business plan devote substantial management attention resource integrate business practice operation celgene fully realize anticipated benefit acquisition nonetheless difficulty arise process combine operation company result failure achieve synergies free cash flow anticipate loss key employee difficult replace competitive pharmaceutical field disruption company ongoing business inconsistency standard control procedure policy adversely affect ability maintain relationship customer supplier distributor alliance partner creditor clinical trial investigator manager clinical trial result anticipate benefit acquisition realize fully expect timeframe long realize cost expect materially impact business cash flow financial condition result operation adversely impact price share combine company addition time attention certain member company management company resource focused completion merger integration business company divert daytoday business operation disrupt company ongoing business business combine company celgene target security class action derivative lawsuit connection acquisition describe item financial statement supplementary datanote legal proceeding contingency target additional action lawsuit result substantial cost delay prevent acquisition complete failure complete pende acquisition celgene negatively impact stock price future business financial result obligation obligation celgene complete merger subject satisfaction waiver number condition assurance condition completion acquisition satisfied waive acquisition complete acquisition consummate reason receive negative reaction shareholder provider vendor regulator employee subject material risk include possibility price common stock security decline extent current market price reflect market assumption acquisition complete event termination merger agreement certain specified circumstance require reimburse expense celgene pay celgene termination fee billion subject litigation relate failure complete merger specifically enforce obligation perform obligation merger agreement addition merger agreement place certain restriction conduct business prior completion merger restriction waiver subject consent celgene prevent make certain acquisition take certain specify action pursue business opportunity pendency merger take pursue restriction place risk materialize materially adversely affect business financial condition financial result rating stock price andor bond price incur significant additional indebtedness finance pende acquisition celgene transaction acquisitionrelate cost connection acquisition limit operating flexibility completion acquisition increase indebtedness include acquisition debt finance approximately billion assumption approximately billion celgene debt result high debttoequity ratio addition celgene shareholder receive tradeable contingent value right share celgene represent right receive cash achievement future regulatory milestone result acquisition increase indebtedness anticipate corporate credit rating decrease rating agency increase indebtedness payment pursuant contingent value right significantly reduce cash flow available fund effort combine business celgene realize expect benefit pende acquisition pursue acquisition engage investment product development capital expenditure dividend payment share repurchase activity thing limit flexibility planning react change challenge relate business industry decrease credit rating increase borrowing cost addition certain circumstance require repurchase celgene outstanding debt security provide assurance sufficient fund expect incur number nonrecurre cost connection acquisition acquisition complete comprise transaction cost facility system consolidation cost employmentrelate cost expect realization efficiency relate integration business offset portion cost net benefit accomplish near term celgene difficulty attract motivating retain executive key employee light propose acquisition specialized scientific managerial nature business celgene rely heavily ability attract retain qualified scientific technical managerial personnel competition qualified personnel pharmaceutical field intense success transaction depend ability retain scientific technical personnel key employee celgene uncertainty effect merger celgene employee adverse effect celgene separately consequently combine business uncertainty impair andor celgene ability attract retain motivate key personnel employee retention particularly challenge pendency merger celgene employee experience uncertainty future role combine business additionally celgene officer employee hold share celgene common stock merger complete officer employee entitle cash andor merger consideration respect share celgene common stock officer employee hold celgene stock option celgene rsus celgene psus celgene rsas subject accelerate vest termination cause andor resignation good reason follow completion merger pursuant employment agreement andor agreement arrangement celgene certain key employee celgene entitle receive severance payment termination cause andor resignation good reason follow completion merger agreement certain key employee celgene potentially resign employment follow specify circumstance set forth applicable agreement include adverse change title authority responsibility compensation benefit primary office location payment individually aggregate retention celgene officer employee difficult furthermore celgene key employee depart risk depart include issue relate uncertainty difficulty integration financial security desire employee combine business incur significant cost retain individual identify hire retain replacement depart employee lose significant expertise talent relate business celgene ability realize anticipate benefit merger materially adversely affect accordingly assurance give able attract retain key employee celgene extent celgene able attract retain employee past pende acquisition celgene consummate stockholder ownership percentage dilute propose acquisition consummate issue celgene shareholder share common stock result issuance share common stock shareholder small percentage combine company acquisition reduce voting interest acquisition base preliminary estimate materially change completion merger propose acquisition expect dilutive gaap ep principally amortization intangible asset associate celgene currently market product right additional interest acquisition integration cost expect transaction accretive nongaap ep unexpected factor result lower delay accretion dilution ep future year combine company subject risk celgene face addition risk face bristolmyer squibb celgene commercialize product diverse early latestage pipeline include potential nearterm product launch consummate acquisition celgene combine company negatively affect expiration loss patent protection commercialize product occur atrisk launch manufacturer generic version product addition combine company fail obtain timely requisite regulatory approval internationally product development research development earlystage pipeline require great financial investment anticipate business cash flow financial condition result operation harm consummate acquisition celgene assume celgene risk arise legal proceeding like pharmaceutical company current legal environment celgene involve patent product liability consumer commercial security environmental tax litigation claim government investigation legal proceeding arise time time ordinary course business predict certainty eventual outcome celgene pende future legal proceeding adverse outcome matter material business cash flow financial condition result operation item b unresolved staff comment item property principal executive office locate east th street th floor new york ny lease manufacturing rd administration storage distribution facility approximately site worldwide believe manufacturing property combination thirdparty manufacturer good operating condition provide adequate production capacity current project operation information manufacturing property refer item businessmanufacture quality assurance significant manufacturing rd location geographic area follow december manufacturing rd united states europe total item legal proceeding information pertain legal proceeding find item financial statement supplementary datanote legal proceeding contingency incorporate reference item safety disclosure applicable ia executive officer registrant list information executive officer february executive officer elect board director initial term continue board meeting follow annual meeting shareholder elect oneyear term successor elect executive officer serve discretion board director current position age employment history past year giovanni caforio md president pharmaceuticals chairman board chief executive officer executive vice president chief commercial officer member leadership team chief operating officer director company chief executive officer director company present chairman board chief executive officer charle bancroft chief financial officer executive vice president global services chief financial officer executive vice president present chief financial officer executive vice president global business global business operation operation member leadership team paul biondi senior vice president rd operation senior vice president strategy business head business development development present senior vice president head strategy business development member leadership team christopher boerner phd senior vice president commercial seattle genetics executive vice president chief commercial officer executive vice president seattle genetics member leadership team president head commercial president head international market present executive vice president chief commercial officer adam dubow vice president assistant general counsel china japan intercon region senior vice president chief compliance ethic emac region officer vice president associate general counsel research development member leadership team present senior vice president chief compliance ethic officer john e elicker senior vice president public affairs investor relation senior vice president corporate affair investor present senior vice president corporate affair investor relation relation member leadership team ann powell judge chief human resource officer shire pharmaceutical senior vice president chief human resource senior vice president global human resource officer present senior vice president chief human resource officer member leadership team sandra leung general counsel corporate secretary executive vice president general counsel executive vice president general counsel corporate secretary member leadership team present executive vice president general counsel thomas j lynch md present executive vice president chief scientific officer executive vice president chief scientific officer member leadership team karen santiago vice president finance global manufacturing supply senior vice president corporate controller vice president finance commercial global capability hub lead enable function finance transformation present senior vice president corporate controller louis schmukler president global product development supply senior vice president president global product present senior vice president president global product development supply development supply member leadership team paul von autenrie senior vice president enterprise service chief information officer senior vice president chief information officer present senior vice president chief information officer member leadership team ii item market registrant common stock stockholder matter bristolmyer squibb common stock trade new york stock exchange symbol bmy holder common stock number record holder common stock january number record holder base actual number holder register book date base information provide eq shareowner service wells fargo shareowner service transfer agent include holder share street name person partnership association corporation entity identify security position listing maintain depository trust company equity compensation plan information information require item contain proxy statement head item vote uponitem advisory vote approve compensation name executive officersequity compensation plan information information incorporate reference performance graph follow graph compare cumulative total stockholder return common share cumulative total stockholder return company list standard poor index composite peer group major pharmaceutical company comprise abbvie amgen astrazeneca biogen celgene gilead glaxosmithkline johnson johnson lilly merck novartis pfizer roche sanofi graph assume investment december common share sp index stock peer group company include reinvestment dividend year end december stock price performance follow graph necessarily indicative future stock price performance bristolmyer squibb sp peer group unregistere sale equity security use proceed follow table summarize surrender equity security month end december total number share approximate dollar value average price purchase share total number pay publicly announce purchase period share purchaseda sharea programsb programsb dollar million share datum october november december month end december include share repurchase publicly announce program share common stock surrender company satisfy tax withholding obligation connection vest award longterm incentive program b board director authorize repurchase billion common stock june increase authorization repurchase common stock additional billion october board director approve new share repurchase program authorize repurchase additional billion common stock stock repurchase program expiration date item select financial datum follow table set forth select historical consolidated financial information period indicate information read item management discussion analysis financial condition result operation consolidate financial statement relate note include select historical financial information year end december derive audit consolidated financial statement relate note year financial summary amount million share datum income statement datum total revenue net earning net earningsloss attributable noncontrolle interest bms net earning common share attributable bms basic diluted average common share outstanding basic diluted cash dividend pay bms common prefer stock cash dividend declare common share financial position datum december cash cash equivalent marketable securitiesa total asset longterm debta equity include current noncurrent portion item management discussion analysis financial condition result operation management discussion analysis result operation financial condition provide supplement read conjunction consolidate financial statement relate note include enhance understanding result operation financial condition cash flow executive summary bristolmyers squibb company global specialty biopharmaceutical company mission discover develop deliver innovative medicine help patient prevail disease refer summary abbreviate term end term document receive approval new medicine additional indication formulation currently market medicine major market eu japan china include multiple regulatory milestone achievement opdivo opdivoyervoy combination commit investigate opdivo combination yervoy anticancer agent wide array tumor type include broad program lung head neck liver kidney bladder stomach continue believe breadth depth io portfolio position future new io compound clinical development study different tumor type addition advance certain nonio rd programs pipeline include tyk inhibitor treatment psoriasis autoimmune disease factor xia inhibitor treatment thrombosis collaboration janssen pegbelfermin pegfgf treatment nash revenue increase result high demand prioritize brand include opdivo eliquis partially offset increase competition establish brand primarily hiv brands daklinza increase gaap ep primarily tax charge attribute tax reform high revenue item partially offset high loss equity investment adjust impact tax reform equity investment loss specify item nongaap eps increase primarily result high revenue high royalty license income low effective tax rate cost saving result transformation initiative continue redeploy rd area high priority january announce enter definitive merger agreement celgene acquire celgene discussion pende acquisition celgene acquisition divestitures license arrangement refer item risk factor item financial statement supplementary datanote acquisition divestitures license arrangement note subsequent event revenue increase result high demand prioritize brand include opdivo eliquis partially offset increase competition establish brand primarily daklinza decrease gaap ep tax charge attribute tax reform share less extent high license asset acquisition restructuring relate charge low divestiture relate income item partially offset high revenue royalty licensing income patentinfringement settlement adjust impact tax reform specify item nongaap eps increase primarily result high revenue partially offset product mix high rd expense support opdivo io program highlight follow table summarize financial information year end december dollar million share datum total revenue dilute earning share gaap nongaap nongaap financial measure include nongaap earning relate eps information adjust exclude specify item represent certain cost expense gain loss item impact comparability financial result detail list specify item information reconciliation nongaap financial measure refer nongaap financial measure significant product pipeline approval follow summary significant approval receive product date approval august approval japan patient mpm progress chemotherapy august approval japan adjuvant treatment melanoma fda approval io treatment option patient metastatic sclc cancer august progress platinumbase chemotherapy line therapy opdivo ec approval adjuvant treatment adult patient melanoma involvement lymph nodes july metastatic disease undergo complete resection approval china treatment locally advanced metastatic nsclc prior platinumbase june chemotherapy adult patient egfr alk genomic tumor aberration august approval japan opdivo plus lowdose yervoy treatment unresectable metastatic rcc fda approval opdivo plus lowdose yervoy treatment adult pediatric patient year july old msih dmmr mcrc progress follow treatment fluoropyrimidine oxaliplatin irinotecan opdivoyervoy approval japan opdivoyervoy combination previously untreated patient unresectable melanoma fda approval opdivoyervoy combination previously untreated patient intermediate poor april risk advanced rcc approval japan intravenously administer treatment moderate severe polyarticular jia orencia february patient year age old fda approval empliciti injection intravenous use combination pomalidomide dexamethasone empliciti november treatment adult patient multiple myeloma receive prior therapy include lenalidomide proteasome inhibitor fda expand indication sprycel include treatment pediatric patient year age december old newly diagnose philadelphia chromosomepositive combination chemotherapy sprycel ec expand indication sprycel include treatment child adolescent aged year july year chronic phase philadelphia chromosomepositive cml include powder oral suspension yervoy january ec approval advance unresectable metastatic melanoma pediatric patient year age old refer product pipeline development development market product latestage pipeline early strategy focus specialty biopharmaceutical company discover develop deliver transformational medicine address unmet medical need strategy combine resource scale capability pharmaceutical company speed focus innovation biotech industry strategic priority drive business performance continue build lead franchise io maintain diversified portfolio outside io continue discipline approach capital allocation include establish partnership collaboration inlicense acquire investigational compound essential component successfully deliver transformational medicine patient develop new medicine follow core therapeutic area oncology priority certain tumor type immunoscience prioritie psoriasis lupus ra inflammatory bowel disease cardiovascular priority heart disease fibrotic disease priority lung liver continue advance wave innovative medicine invest significantly pipeline internally business development activity expect plan acquisition celgene position lead biopharmaceutical company expand oncology immunoscience portfolio nearterm asset additional external partnership continue invest io portfolio pursue monotherapy combination approach advance wave early asset enter new collaboration agreement therapeutic area focus expand research develop opdivo approve investigational oncology agent combination regimen remain focused resource cancer development program seek broaden use opdivo early line therapy expand new tumor accelerate wave io mechanism develop treatment option refractory io patient cancer continue advance early stage portfolio immunoscience cardiovascular fibrotic disease strengthen partnership diverse group company academic institution new expand research activity believe differentiate internal external focus contribute advance pipeline potentially transformational medicine commercial model evolve revenue prioritize brand continue grow demonstrate strong execution strategy continue drive growth opdivo expand additional indication tumor type monotherapy combination yervoy anti cancer agent eliquis continue grow leverage good class clinical profile extensive real world datum number novel oral anticoagulant total prescription build continue success prioritize brand remain strongly commit orencia sprycel operating model transformation commercial infrastructure uniquely leverage potential growth operating model continue evolve successful focus commercial rd manufacturing resource prioritize brand market strengthen rd capability tumor biology patient selection new biomarker deliver lean administrative function streamline manufacture network reflect importance biologic current future portfolio evolution operating model focus maintain discipline approach marketing sell administrative expense enable deliver necessary strategic financial operational flexibility invest high priority opportunity portfolio look ahead continue implement biopharma strategy drive growth prioritize brand execute product launch invest diverse innovative pipeline aid strategic business development focus prioritize market increase investment biologic manufacturing capability maintain culture continuous improvement acquisition divestiture license collaboration arrangement acquisition divestiture license collaboration arrangement allow focus resource growth opportunity drive great long term value focus follow core therapeutic area oncology include io immunoscience cardiovascular fibrosis significant acquisition divestiture license collaboration arrangement past year summarize refer item financial statement supplementary datum note alliance note acquisition divestiture license arrangement information arrangement nektar bms nektar commence worldwide license collaboration development commercialization nktr nektars investigational immunostimulatory therapy janssen bms janssen commence worldwide collaboration development commercialization factor xia program include bmss factor xia inhibitor bms investigational anticoagulant compound study prevention treatment major thrombotic condition promedior bms notify promedior company exercise warrant obtain purchase outstanding share promedior rigel bms notify rigel pharmaceuticals inc company discontinue participation preclinical collaboration cancer immunotherapy base rigel small molecule tgf beta receptor kinase inhibitor originally commence bavarian nordic bms notify bavarian nordic company exercise option globally license commercialize prostvac bavarian nordics investigational psatargeting cancer immunotherapy arrangement ono bms acquire exclusive license develop commercialize ono onos prostaglandin e receptor antagonist treatment cancer bm acquire worldwide right japan south korea taiwan add exist collaboration china asean country ono retain exclusive right halozyme bms halozyme enter global collaboration license agreement develop subcutaneously administer bms io medicine halozyme enhanze drugdelivery technology allow rapid delivery large volume injectable medication ifm bms acquire outstanding share ifm provide bms right ifm preclinical sting nlrp agonist program focus enhance innate immune response treat cancer biogen bms outlicense biogen exclusive right develop commercialize bms antietau compound development progressive supranuclear palsy roche bms outlicense roche exclusive right develop commercialize bms antimyostatin adnectin development duchenne muscular dystrophy cytomx bms cytomx expand initial strategic collaboration discover novel cancer treatment therapy include additional target cytomxs proprietary probody platform treatment cancer arrangement psioxus bms acquire exclusive worldwide right psioxus ng preclinical stage armed oncolytic virus goal address solid tumor padlock bms acquire outstanding share padlock provide bms right padlock pad inhibitor discovery program focus development treatment approach patient ra cormorant bms acquire outstanding share cormorant provide bms right cormorant lead candidate humaxil monoclonal antibody represent potentially complementary io mechanism action tcell direct antibodie costimulatory molecules nitto denko bms acquire exclusive worldwide license develop commercialize nitto denko investigational sirna molecule target heat shock protein hsp vitamin contain formulation include nitto denko lead asset ndls currently development treatment advance liver fibrosis option receive exclusive license hsp sirnas vitamin contain formulation treatment lung organ fibrosis result operation regional revenue composition change revenue follow year end december vs vs total revenue analysis change analysis change total foreign total foreign dollar million change exchangeb change exchangeb united states europe rest world othera na na total revenue include royalty alliancerelate revenue product sell regional commercial organization b foreign exchange impact derive apply prior period average currency rate current period sale revenue impact high demand opdivo eliquis partially offset low demand establish brand increase competition primarily hiv brand daklinza high growth rate additional indication approval opdivo average net selling price unchanged chargeback rebate discount refer product revenue commentary additional information europe revenue impact high demand eliquis opdivo foreign exchange partially offset low demand establish brand increase competition low average net selling price rest world revenue impact low demand establish brand increase competition low average net selling price foreign exchange partially offset high demand opdivo eliquis revenue impact high demand eliquis opdivo partially offset low demand establish brand increase competition primarily daklinza hiv brand average net selling price approximately high chargeback rebate discount refer product revenue commentary additional information europe revenue impact high demand opdivo eliquis partially offset low demand daklinza increase competition low average net selling price rest world revenue impact low demand establish brand include daklinza increase competition outlicense mature brand product partially offset high demand opdivo eliquis low average net selling price single country outside contribute total revenue gtn adjustment recognize revenue net gtn adjustment describe critical accounting policy activity end reserve balance significant category gtn adjustment follow rebate chargeback medicaid return discount dollar million cash discount medicare rebate adjustment total balance january provision relate sale current period prior period payment return foreign currency translation balance december provision relate sale current period prior period payment return assetsrelate liability heldforsale foreign currency translation balance december reconciliation gross product sale net product sale significant category gtn adjustment follow year end december change dollar million vs vs gross product sale gtn adjustment chargeback cash discount medicaid medicare rebate rebate return discount adjustment total gtn adjustment net product sale gtn adjustment percentage nonus gtn adjustment primarily function product sale volume regional payer channel mix contractual legislative discount rebate gtn adjustment increase high rate gross product sale high eliquis gross product sale relatively high gtn adjustment percentage result competitive pressure maintain position healthcare payer formulary allow patient continue access medical plan product revenue year end december change dollar million vs vs prioritize brand opdivo nonus eliquis nonus orencia nonus sprycel nonus yervoy nonus empliciti nonus establish brand baraclude nonus reyataz franchise nonus sustiva franchise nonus hepatitis c franchise nonus brand nonus total revenue nonus change excess opdivo nivolumab fully human monoclonal antibody bind pd nkt cell approve anticancer indication include bladder blood colon head neck kidney liver lung melanoma stomach continues investigate tumor type disease area revenue increase period high demand high growth rate primarily approval treatment adjuvant melanoma liver cancer opdivoyervoy combination kidney cancer partially offset decline lung cancer indication international revenue increase period high demand result approval additional indication launch new country low growth rate primarily additional competition opdivo nsclc indication eliquis apixaban oral factor xa inhibitor target stroke prevention adult patient nvaf prevention treatment vte disorder revenue increase period market share gain partially offset low average net selling price international revenue increase period high demand attribute market share gain growth novel oral anticoagulant market orencia abatacept fusion protein indicate adult patient moderate severe active ra psa indicate reduce sign symptom certain pediatric patient moderately severely active polyarticular jia revenues increase period high demand high average net selling price international revenue increase period high demand experience additional competition europe biosimilar competitor product future period sprycel dasatinib oral inhibitor multiple tyrosine kinase indicate firstline treatment adult philadelphia chromosomepositive cml chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase cml resistance intolerance prior therapy include gleevec imatinib mesylate revenue decrease inventory workdown offset high average net selling price revenue increase high demand high average net selling price international revenue remain unchanged international revenue increase high demand experience decline european revenue event generic datasinib product enter market yervoy ipilimumab monoclonal antibody treatment patient unresectable metastatic melanoma revenue increase period high demand revenue growth rate decrease low demand result io product adjuvant treatment patient melanoma include opdivo international revenue increase period high demand primarily europe follow approval opdivoyervoy combination therapy melanoma baraclude entecavir oral antiviral agent treatment chronic hepatitis b international revenue decrease period low demand result increase competition reyataz atazanavir sulfate franchise include reyataz protease inhibitor treatment hiv evotaz atazanavir mg cobicistat mg combination therapy contain reyataz tybost cobicistat loe reyataz occur december result revenue continue decline international revenue decrease period low demand result increase competition sustiva efavirenz franchise nonnucleoside reverse transcriptase inhibitor treatment hiv include sustiva antiretroviral drug bulk efavirenz include combination therapy atripla loe sustiva occur december gilead terminate bms participation canada joint venture follow launch generic version sustiva result bms share atripla revenue decline year refer item financial statementsnote alliance discussion international revenue include million atripla royalty revenue hepatitis c franchise daklinza daclatasvir nsa replication complex inhibitor sunvepra asunaprevir ns protease inhibitor beclabuvir nsb inhibitor international revenue decrease period low demand result increase competition brand include brand include lose exclusivity major market otc brand royalty revenue international revenue decrease primarily low plavix royalty result adoption amend revenue guidance expiration right abilify canada low diabete product supply sale continue generic erosion revenue decrease outlicense divestiture certain brand continue generic erosion estimate endus demand pursuant sec consent order describe sec consent order monitor level inventory hand wholesaler distribution channel outside direct customer distribution channel obligate disclose product level inventory excess month hand expect demand subject de minimis exception estimate level inventory distribution channel excess month hand follow product material result operation date indicate december daklinza month inventory hand result minimum require stock level support patient demand expect inventory hand level daklinza exceed month near term international product estimate level inventory distribution channel excess month hand september dafalgan analgesic product sell principally europe month inventory hand internationally direct customer compare month inventory hand june level inventory hand primarily order pattern pharmacist france efferalgan analgesic product sell principally europe month inventory hand internationally direct customer compare month inventory hand june level inventory hand primarily order pattern pharmacist france fervex cold flu product month inventory hand direct customer compare month inventory hand june level inventory hand primarily order pattern pharmacist france daklinza hepatitis c product month inventory hand internationally direct customer compare month inventory hand june level inventory hand attributable low volume inmarket sale canada perfalgan analgesic product month inventory hand internationally direct customer compare month inventory hand june level inventory hand primarily gulf country extend delivery lead time sustiva hiv product month inventory hand internationally direct customer compare month inventory hand june level inventory hand attributable low volume inmarket sale canada generally determine month hand estimate inventory level product hand outmovement provide large wholesaler account approximately total gross sale product factor influence estimate include generic competition seasonality product wholesaler purchase light increase wholesaler list price new product launch new warehouse opening wholesaler new customer stocking wholesaler addition estimate calculate thirdparty datum impact recordkeeping process nonus business significantly direct customer information available direct customer product level inventory correspond movement information reliability thirdparty demand information vary widely limit direct customer sale channel inventory report influence demand information exist available develop variety methodology estimate datum include historical sale direct customer thirdparty market research datum relate prescription trend endus demand give difficulty inherent estimate thirdparty demand information evaluate methodology estimate direct customer product level inventory calculate month hand ongoing basis change necessary factor affect estimate include generic competition seasonality product price increase new product launch new warehouse opening direct customer new customer stocking direct customer expect direct customer purchase governmental bidding situation information require estimate month hand direct customer distribution channel nonus business year end december available prior filing disclose product level inventory excess month hand expect demand subject de minimis exception quarterly report form q expense change dollar million vs vs cost product sell marketing sell administrative research development income net total expense cost product sell cost product sell include material internal labor overhead cost own manufacturing site thirdparty product supply cost supply chain cost manage global manufacturing supply organization cost product sell include royalty profit share certain excise taxis foreign currency hedge settlement gain loss amortization acquire develop technology cost cost product sell typically vary period result product mix volume particularly royaltie profit share less extent change foreign currency price inflation cost attribute manufacturing site exit cost product sell increase high royalty profit share million result primarily high eliquis sale partially offset product cost improvement million impairment charge reduce carry value small molecule active pharmaceutical ingredient manufacturing operation sword ireland low inventory charge cost product sell increase high royalty profit share million result primarily high eliquis sale million impairment charge discuss remain increase primarily high sale volume inventory charge manufacture startup cost foreign currency marketing sell administrative marketing sell administrative expense primarily include salary benefit cost thirdparty professional marketing fee outsource fee shipping handling cost advertising product promotion expense manage regional commercialization organization global enable function finance legal information technology human resource certain expense share alliance partner base contractual agreement expense typically vary period new product launch promotional activity marketing sell administrative expense decrease low advertising promotion marketing expense low cost attribute transformation initiative lower brand prescription drug fee partially offset high bms foundation grant marketing sell administrative expense decrease low advertising promotion salesforce expense support daklinza establish brand low bms foundation grant research development research development activity include discovery research preclinical clinical development drug formulation medical support market product expense include salary benefit cost thirdparty grant fee pay clinical research organization supply upfront contingent milestone payment license asset acquisition investigational compound iprd impairment charge proportionate allocation enterprisewide cost allocation include facility information technology employee stock compensation cost appropriate cost certain expense share alliance partner base contractual agreement expense typically vary period number reason include time license asset acquisition charge iprd impairment charge research development expense decrease low site exit cost iprd impairment charge partially offset expansion opdivo io development program include nktr research development expense increase high license asset acquisition charge site exit charge iprd impairment charge expansion opdivo io development program significant charge include rd expense follow year end december dollar millions nektar cormorant b ifm b cytomx halozyme flexus b b cardioxyl b psioxus ono padlock nitto denko license asset acquisition charge fstar iprd impairment site exit cost research development significant charge upfront payment b milestone payment license asset acquisition charge result strategic transaction acquire license certain investigational oncology cardiovascular immunoscience fibrotic disease compound option acquire license disclose acquisition divestiture license collaboration arrangement iprd impairment charge include discontinue development investigational compound alliance fstar site exit cost result expect exit rd site primarily reduction estimate useful life relate asset impairment charge reduce carry value rd facility wallingford connecticut income net income net decrease primarily loss equity investment relate nektar patent infringement settlement partially offset low restructure debt redemption charge income net increase primarily patent infringement settlement outlicense income partially offset low divestiture gain relate service fee high restructure debt redemption charge component income net follow year end december dollar million interest expense investment income lossgain equity investment provision restructure litigation settlement equity net income affiliate divestiture gain royalty license income transition service fee pension postretirement intangible asset impairment loss debt redemption income net lossgain equity investment include fair value adjustment million relate company equity investment nektar restructuring charge relate change company operating model drive continue success near longterm focus investment commercial opportunity key brand market competitive agile rd organization accelerate pipeline streamline operation realign manufacturing capability broaden biologic capability reflect current future portfolio streamline simplify smallmolecule supply network new operating model expect enable company deliver strategic financial operational flexibility necessary invest high priority company aggregate restructuring charge million million incur respectively action include accelerate depreciation impairment charge result early site exit litigation settlement include million bms share patentinfringement settlement relate merck pd antibody keytruda million relate intellectual property product liability settlement include million recognize subsequent company earning release fourth quarter divestiture gain include divestiture multiple mature global product line oncology infectious therapy additional contingent consideration diabete business certain otc brand investigational hiv medicine business royalty licensing income include keytruda royalty upfront licensing fee biogen roche connection license certain investigational genetically define disease compound contingent consideration erbitux diabetes business divestiture including transfer certain royalty right pertaining diabete product sale million fee amend royalty rate million salesbase milestone include transition service fee include fee result divestiture diabete investigational hiv medicine business pension postretirement include interest cost expect return plan asset amortization component net periodic benefit cost credit net charge settlement curtailment special termination benefit million million million intangible asset impairment include million outlicense asset obtain acquisition zymogenetics inc meet primary endpoint phase ii clinical study debt redemption loss million result early redemption certain longterm debt obligation income taxis dollar million earning income taxis provision income taxis effective tax rate impact specify item change effective tax rate primarily new tax reform legislation know tax cut job act act enact december act move worldwide tax system quasiterritorial tax system comprise broad complex change tax code include limited reduce tax rate add deem repatriation transition tax certain foreign earning profit generally eliminate federal income taxis dividend foreign subsidiary include certain income control foreign company taxable income gilti create new minimum tax refer base erosion antiabuse income tax limit certain researchbase credit eliminate domestic manufacturing deduction aspect act effective additional tax expense billion recognize fourth quarter enactment act additional expense increase effective tax rate include billion onetime deem repatriation transition tax previously untaxe post foreign earning profit include related tax reserve earning effectively tax rate extent specify foreign corporation hold cash certain asset rate remain earning profit remain million additional tax expense include adjustment measure net defer tax asset new tax rate accounting reduction defer tax asset tax rate complete december provisional tax charge deem repatriation transition tax reduce million completion accounting reduce effective tax rate addition tax impact attribute specify item include nondeductible rd charge valuation allowance certain tax asset result equity investment loss jurisdiction tax rate increase effective tax rate consider impact specify item include transitional impact act discuss effective tax rate decrease primarily ongoing impact act tax reserve release partially offset taxis attribute internal cash repatriation earning mix high low tax jurisdiction consider impact specify item effective tax rate decrease primarily adoption amend income tax accounting guidance relate sharebased payment early adoption intraentity transfer asset inventory partially offset earning mix high low tax jurisdiction refer item financial statement supplementary datanote income taxis information nongaap financial measure nongaap financial measure include nongaap earning relate eps information adjust exclude certain cost expense gain loss specify item evaluate individual basis item adjust consider quantitative qualitative aspect typically follow characteristic highly variable difficult project unusual nature significant result particular period indicative future operating result similar charge gain recognize prior period likely reoccur future period include restructuring cost accelerate depreciation impairment property plant equipment intangible asset rd charge connection acquisition license party intellectual property right divestiture gain loss pension legal contractual settlement charge debt redemption gain loss item defer current income taxis attribute item adjust consider individual impact overall tax expense deductibility jurisdictional tax rate nongaap information intend portray result baseline performance supplement enhance management analyst investor overall understanding underlie financial performance facilitate comparison current past future period example nongaap earning ep information indication baseline performance item consider reflective ongoing result addition information primary indicator use basis evaluate performance allocate resource set incentive compensation target planning forecast future period information intend consider isolation substitute net earning dilute eps prepared accordance gaap specify item follow year end december dollar million impairment charge accelerate depreciation shutdown cost cost product sell marketing sell administrative license asset acquisition charge iprd impairment site exit cost research development lossgain equity investmentsa provision restructure litigation settlement divestiture gain royalty license income pension postretirement intangible asset impairment loss debt redemption income net increase pretax income income taxis item income taxis attribute tax reform income taxis increase net earning noncontrolle interest increase net earning diluted nongaap eps calculation specify item include amount adoption amend guidance recognition measurement financial asset liability reconciliations gaap nongaap follow year end december dollar million share datum net earning attributable bms diluted eps calculation gaap specify item net earning attributable bms diluted eps calculation nongaap average common share outstanding dilute diluted eps attributable bms gaap dilute eps attributable specify item dilute eps attributable bms nongaap financial position liquidity capital resource net cash position follow dollar million cash cash equivalent marketable security current marketable security noncurrent total cash cash equivalent marketable security shortterm debt obligation longterm debt net cash position cash cash equivalent marketable security hold approximately billion december remain billion hold primarily international affiliate local operating need subject onetime deem repatriation transition tax billion payable year result tax reform expect flexibility access cash future cash generate foreign subsidiary believe exist cash cash equivalent marketable security cash generate operation issuance commercial paper sufficient satisfy normal cash requirement year include dividend capital expenditure milestone payment working capital deem repatriation transition tax billion debt mature management continuously evaluate company capital structure ensure company finance efficiently result repurchase common stock debt security termination interest rate swap contract prior maturity issuance debt security average commercial paper outstanding million weightedaverage rate maximum commercial paper outstanding million outstanding borrowing december dividend payment billion billion dividend decision quarterly basis board director annual capital expenditure approximately billion billion billion expect approximately million million continue expand biologic manufacturing capability facilityrelate activity example construct new large scale biologic manufacturing facility ireland produce multiple therapy grow biologic portfolio approve commercial use early pay billion nektar certain collaboration right million share common stock represent ownership interest investment portfolio include noncurrent marketable security subject change fair value result interest rate fluctuation market factor investment policy establishe limit time maturity investment institution policy require investment enter corporate financial institution meet high credit quality standard refer item financial statement supplementary datanote financial instrument fair value measurement information december revolve credit facility total billion consist day billion facility schedule expire march fiveyear billion facility extend september july respectively facility provide customary term condition financial covenant billion revolving facility extendable annually year anniversary date consent lender borrowing outstanding revolve facility december connection pende acquisition celgene january enter bridge commitment letter provide billion day senior unsecured bridge loan facility enter billion term loan credit agreement consist billion day tranche billion threeyear tranche billion fiveyear tranche term loan reduce commitment bridge facility billion obtain additional funding issue security obtain loan bridge facility correspondingly reduce bridge loan term loan subject customary term condition financial covenant amount borrow bridge loan term loan prior close pende acquisition celgene january enter new revolve credit facility total billion day billion facility expire january threeyear billion facility expire january day billion facility replace exist day billion revolving facility terminate concurrently effectiveness new day facility support commercial paper borrowing facility provide customary term condition financial covenant borrowing outstanding revolve facility billion revolve facility february follow announcement pende acquisition celgene enter forward start interest rate swap option contract swaption total notional value billion hedge future interest rate risk associate anticipate issuance longterm debt fund acquisition swaption provide right enter forward start interest rate swap contract period year january additional regulation pass future include additional healthcare reform initiative change tax law additional pricing law potential importation restriction reduce result operation operate cash flow liquidity financial flexibility continue monitor potential impact economic condition certain european country relate impact prescription trend pricing discount creditworthiness customer believe economic condition material impact liquidity cash flow financial flexibility uk vote depart eu june similar company industry certain regulatory trade labor aspect business likely affect time currently believe matter relate financial effect material impact consolidate result operation financial position liquidity sale uk represent consolidate revenue credit rating january moody place bms review downgrade standard poor place bms creditwatch negative implication follow announcement acquire celgene bms current longterm shortterm credit rating assign moody investor service prime respectively bms current longterm shortterm credit rating assign standard poor respectively longterm rating reflect agency opinion low default risk somewhat susceptible adverse effect change circumstance economic condition shortterm rating reflect agency opinion good extremely strong capacity timely repayment credit rating downgrade affect interest rate debt incur fair market value exist debt ability access capital market generally current longterm short term rating reflect impact propose acquisition celgene cash flow follow discussion cash flow activity dollar million cash flow provide byused operating activity invest activity financing activity operate activity cash flow operating activity represent cash receipt disbursement activity invest financing activity operate cash flow derive adjust net earning noncontrolle interest noncash operating item gain loss attribute invest financing activity change operate asset liability result time difference receipt payment cash transaction recognize result operation result change cash operating activity reflect time cash collection customer alliance partner payment supplier alliance partner employee customer discount rebate tax payment ordinary course business example annual employee bonus typically pay quarter subsequent year addition cash collection continue impact long payment term certain biologic product primarily new oncology product include opdivo yervoy empliciti day day long payment term closely align insurance reimbursement time physician cancer center follow administration patient million change cash flow operating activity compare primarily attributable high cash collection time payment ordinary course business approximately billion partially offset high rd licensing collaboration payment approximately million primarily nektar transaction low litigation settlement proceed approximately million primarily merck settlement low outlicense proceed approximately million primarily biogen roche transaction billion change cash flow operating activity compare primarily attributable high cash collection time payment ordinary course business approximately million low income tax payment approximately billion litigation settlement proceed approximately million primarily merck settlement outlicensing proceed million primarily biogen roche transaction partially offset high rd licensing payment approximately million primarily cytomx halozyme nitto denko transaction high contribution pension plan approximately million investing activity cash requirement invest activity include cash acquisition manufacturing facilityrelate capital expenditure purchase marketable security original maturity great day time purchase reduce proceed business divestiture include royalty sale maturity marketable security million change cash flow investing activity compare primarily attributable low net sale maturity marketable security maturity great day approximately million high net acquisition payment approximately million primarily purchase million share nektar common stock partially offset high business divestiture proceed approximately million primarily divestiture manufacturing operation sword ireland certain mature brand billion change cash flow investing activity compare primarily attributable low net sale marketable security maturity great day approximately million low business divestiture proceed approximately million primarily certain otc brand investigational hiv medicine business high asset acquisition payment approximately million primarily acquisition ifm financing activity cash requirement financing activity include cash pay dividend repurchase common stock repay longterm debt borrowing reduce proceed exercise stock option issuance longterm debt borrowing million change cash flow financing activity compare primarily attributable low repurchase common stock billion primarily accelerated share repurchase agreement partially offset low net borrowing billion primarily issuance longterm debt repurchase common stock billion change cash flow financing activity compare primarily attributable high repurchase common stock billion primarily accelerated share repurchase agreement partially offset high net borrowing activity million primarily fund repurchase common stock contractual obligation offbalance sheet arrangement payment period contractual obligation december follow obligation expire period dollar million total later year shortterm borrowing longterm debt interest longterm debta operating lease purchase obligation uncertain tax positionsb deem repatriation transition tax total c include estimate future interest payment periodic cash settlement derivative b include shortterm uncertain tax benefit uncertainty timing resolution c exclude pension liability uncertainty timing resolution addition commit aggregate billion potential future research development milestone payment party license asset acquisition development program include earlystage milestone billion milestone achieve phase iii clinical study latestage milestone billion milestone achieve post phase iii clinical study payment generally payable achievement certain developmental regulatory milestone specific timing predict agreement provide salesbased milestone aggregate billion obligate pay alliance partner achievement certain sale level addition royalty certain manufacturing development commercialization obligation connection alliance arrangement practicable estimate obligation refer item financial statement supplementary datanote alliance information alliance offbalance sheet arrangement material reasonably likely material financial condition result operation sec consent order fcpa settlement previously disclose august enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter settlement reach consent copy attach exhibit quarterly report form q period end september term consent agree subject certain define exception limit sale product sell direct customer include wholesaler distributor hospital retail outlet pharmacie government purchaser base expect demand amount exceed approximately month inventory hand make timely public disclosure change practice agree consent certain measure implement include establish formal review certification process annual quarterly report file sec b establish business risk disclosure group c retain outside consultant comprehensively study help reengineer accounting financial reporting process publicly disclose sale incentive offer direct customer purpose induce purchase product excess expect demand e ensure budget process give appropriate weight input come adequately document process establish companywide policy limit sale direct customer purpose comply consent policy include adoption procedure monitor limit sale direct customer accordance term consent procedure include governance process escalate appropriate management level potential question concern compliance policy timely resolution question concern addition compliance policy monitor regular basis maintain dsas pharmaceutical wholesaler account nearly gross revenue current term dsas wholesaler customer provide weekly information respect month hand productlevel inventory outmovement product large wholesaler currently account approximately gross revenue inventory information receive wholesaler internal information estimate month hand product level inventory wholesaler estimate month hand product inventory level businesss wholesaler customer large wholesaler extrapolate month hand calculate large wholesaler contrast nonus business significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely accordingly rely variety method estimate month hand product level inventory business unit believe abovedescribe procedure provide reasonable basis ensure compliance consent recently issue accounting standard recently issue accounting standard refer item financial statement supplementary datanote accounting policy recently issue accounting standard critical accounting policy preparation financial statement require use estimate assumption affect report amount asset liability report amount revenue expense critical accounting policy significantly impact financial condition result operation require difficult subjective complex judgment result need estimate effect matter inherently uncertain uncertainty actual result vary estimate revenue recognition accounting policy revenue recognition substantial impact report result rely certain estimate revenue recognize follow step model identify customer contract identify contract performance obligation determine transaction price allocate transaction price performance obligation recognize revenue performance obligation satisfied revenue reduce gtn sale adjustment discuss involve significant estimate judgment consider legal interpretation applicable law regulation historical experience payer channel mix eg medicare medicaid current contract price applicable program unbilled claim processing time lag inventory level distribution channel estimate assess period adjust require revise information actual experience gtn adjustment follow category gtn adjustment involve significant estimate judgment information obtain external source refer item financial statement supplementary datanote revenue discussion analysis significant category gtn sale adjustment chargeback cash discount business participate program government entity significant department defense department veteran affair party include cover entity b drug pricing program pricing product extend wholesaler list price participate entity entity purchase product wholesaler low program price wholesaler charge difference acquisition cost low program price account receivable reduce estimate unprocessed chargeback claim attributable sale typically week time lag certain country cash discount offer incentive prompt payment generally approximate sale price account receivable reduce estimate unprocessed cash discount typically month time lag medicaid medicare rebate business participate state government medicaid program qualify federal state government program require discount rebate participate state local government entity discount rebate provide program include medicaid rebate accrual medicaid rebate extend drug manage medicaid plan estimate unpaid unbilled rebate present liability rebate discount offer manage healthcare organization manage prescription drug program medicare advantage prescription drug plan cover medicare drug benefit pay point service discount cms medicare beneficiarie coverage gap donut hole estimate unpaid unbilled rebate discount present liability rebate return discount adjustment gtn sale adjustment include sale return program base applicable law regulation individual nonus country rebate offer manage healthcare organization less extent nonus program include different pricing scheme cost cap volume discount outcomebase pricing scheme pricing clawback base sale individual company aggregation company participate specific market estimate unpaid unbilled rebate discount present liability estimate return establish product determine consider historical experience factor include level inventory distribution channel estimate shelf life product recall product discontinuance price change competitive product introduction generic product introduction competitive new product low demand follow loe estimate return new product determine consider historical sale return experience similar product product line similar therapeutic area andor similar distribution model estimate level inventory distribution channel project demand estimate product return present liability use information external source information external source estimate gtn adjustment estimate inventory wholesaler base project prescription demand base sale product historical inventory experience analysis thirdparty information include write oral information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum internal information inventory information receive wholesaler product recordkeeping process exclude inventory hold intermediary sell retailer hospital continue practice combine retail mail prescription volume retailequivalent basis use methodology internal demand forecast use information external source identify prescription trend patient demand average selling price estimate subject inherent limitation estimate rely thirdparty information certain thirdparty information form estimate reflect limitation include lags date thirdparty information generate date receive thirdparty information pension benefit account pension postretirement benefit plan require actuarial valuation base significant assumption discount rate expect longterm rate return plan asset consultation actuary significant assumption salary growth retirement turnover lump sum election rate healthcare trend mortality rate evaluate select base expectation actual experience remeasurement date pension expense vary range outcome material effect report earning project benefit obligation future cash fund actual result give year differ estimate economic factor yield high quality corporate bond coincide cash flow plan estimate payout determine discount rate citi pension discount curve plan present value benefit obligation december pension plan determine discount rate assume discount rate determine pension plan project benefit obligation december reduce additional project benefit obligation increase approximately million expect longterm rate return plan asset estimate consider expect return individual asset class input external advisor consider longterm historical return include actual performance compare benchmark similar investment bristolmyers squibb retirement income plan pension expense determine average expect longterm rate return plan asset plan pension expense determine expect longterm rate return plan asset expect longterm rate return plan asset determine plan pension expense reduce expense increase million detailed discussion retirement benefit refer item financial statement supplementary datanote retirement benefit longlive asset intangible asset intangible asset billion december include license million million allocate unapproved product develop technology right million capitalize software million iprd million intangible asset assess impairment current fact circumstance warrant review iprd assess annually intangible asset highly vulnerable impairment charge particularly newly acquire asset recently launch product iprd asset initially measure fair value reduction expectation valuation potentially lead impairment common potential risk leading impairment include competition early expect loe pricing pressure adverse regulatory change clinical study result delay failure obtain regulatory approval additional development cost inability achieve expect synergy high operating cost change tax law macroeconomic change complexity estimate fair value intangible asset connection impairment test similar initial valuation property plant equipment property plant equipment test impairment current fact circumstance require review include likely asset dispose prior estimate remain useful life additionally longlive asset periodically review determine change fact circumstance result change estimate useful life asset possibly result acceleration depreciation circumstance exist estimate undiscounted future cash flow generate asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value expectation future cash flow subject change base near longterm production volume margin generate asset potential alternative future use accelerate depreciation impairment relate charge certain manufacturing rd facility million million million additional charge continue occur result company restructuring action announce asset heldforsale follow criterion consider concluding asset classify heldforsale management commitment plan sell availability immediate sale present condition initiation active program identify buyer probability complete sale year actively market sale reasonable price relation current fair value likelihood significant change plan plan withdraw criterion meet balance sheet date asset liability present separately balance sheet heldforsale low carrying fair value cost sell long depreciate amortize classify heldforsale classify million asset million liability heldforsale december relate plan sale upsa consumer health business division bms manufacture market pain treatment otc product domestic sale france export sale outside france income taxis valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment defer tax asset billion december net valuation allowance billion billion december net valuation allowance billion federal net operating loss carryforward million december carryforward acquire result certain acquisition subject limitation section internal revenue code net operating loss carryforward expire vary amount begin foreign state net operating loss carryforward expire vary amount begin certain amount unlimited life discuss fully item financial statement supplementary datanote income taxis provisional tax charge billion attributable onetime deem repatriation transition tax certain foreign earning recognize fourth quarter accounting reduction defer tax asset tax rate complete december tax charge deem repatriation transition tax complete december provisional tax charge deem repatriation transition tax reduce million prior mead johnson splitoff follow transaction occur internal spinoff mead johnson share own ii conversion mead johnson class b share class share iii conversion mead johnson company limited liability company transaction splitoff mead johnson exchange offer qualify taxexempt transaction internal revenue code base private letter ruling receive internal revenue service relate conversion mead johnson class b share class share outside legal opinion certain assumption representation covenant mead johnson rely future conduct business matter affect tax treatment exchange example current tax law generally create presumption exchange taxable mead johnson shareholders engage transaction result great change stock ownership year period begin year exchange offer establish exchange offer plan series relate transaction effect change ownership internal spinoff exchange offer determine qualify tax exempt transaction transaction subject tax exchange taxable sale market value addition negative basis excess loss account ela exist investment stock mead johnson prior transaction receive opinion outside legal counsel effect likely eliminate ela transaction taxable income respect ela tax law area complex possible internal spinoff exchange offer tax exempt internal revenue code irs assert additional taxable income period respect ela expose additional taxis occur base understand internal revenue code opinion outside legal counsel tax reserve million establish reduce gain disposal mead johnson include discontinued operation agree certain tax relate indemnity mead johnson set forth tax sharing agreement include certain taxis relate business prior completion ipo create restructure facilitate ipo mead johnson agree indemnify potential tax effect result breach certain representation discuss certain transaction relate acquisition mead johnson stock asset liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know discussion income taxis refer item financial statement supplementary datanote accounting policy recently issue accounting standardsincome taxis note income taxis contingency normal course business subject contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter recognize accrual contingency probable liability incur loss reasonably estimate estimate subject uncertainty difficult predict actual result vary estimate discussion contingency refer item financial statement supplementary datanote accounting policy recently issue accounting standardscontingencie note income taxis note legal proceeding contingency product pipeline development rd program manage portfolio basis early discovery latestage development include balance earlystage latestage program support future growth late stage rd program phase iii development include investigational compound initial indication additional indication formulation market product spending program represent approximately annual rd expense year opdivo investigational compound market product represent great rd expense year latestage development program potentially impact revenue earning year regulatory approval obtain product successfully commercialize follow development market product latestage pipeline product indication date development august approval japan treatment adjuvant melanoma ec approval adjuvant treatment adult patient involvement lymph nodes metastatic disease july undergone complete resection melanoma announce result phase iii checkmate trial evaluate opdivo versus yervoy patient stage iiibc stage iv melanoma high risk recurrence follow complete surgical resection june demonstrate statistically long recurrencefree survival opdivo primary endpoint study versus yervoy minimum followup month key subgroup include disease stage braf mutation status announce june fda lift partial clinical hold place checkmate randomize openlabel phase iii study evaluating addition opdivo pomalidomide dexamethasone patient multiple myeloma juneaugust relapse refractory multiple myeloma decision follow consultation fda agreement amendment study protocol august company discontinue enrollment study follow futility analysis approval china treatment locally advanced metastatic nsclc prior platinumbase june chemotherapy adult patient egfr alk genomic tumor aberration nsclc announce pivotal randomize phase iii checkmate trial evaluate opdivo versus docetaxel april predominantly chinese population previously treat advanced nsclc demonstrate superior overall survival benefit primary endpoint regardless pdl expression tumor histology acceptance china sbla filing patient previously treat metastatic recurrent january scchn scchn announce twoyear overall survival datum checkmate phase iii study evaluating opdivo compare opdivo april investigator choice chemotherapy cetuximab docetaxel methotrexate patient recurrent metastatic scchn failure platinumbase therapy announce topline result phase iii checkmate study meet primary endpoint october overall survival opdivo versus chemotherapy patient previously treat relapse sclc sclc fda approval io treatment option patient metastatic sclc cancer august progress platinumbase chemotherapy line therapy august approval japan patient mpm progress chemotherapy approval japan week minute infusion dose administration schedule opdivo august indication announce preliminary datum ongoing pivot phase iii study evaluate combination opdivo nektar investigational medicine nktr preliminary result present june american society clinical oncology report safety efficacy biomarker datum patient enrol phase doseescalation stage study patient consecutively enrol select dose expansion cohort phase ii ec approval fourweek qw opdivo dose schedule mg infuse minute option patient advance melanoma previously treat rcc approval twoweek april opdivo dosing option mg infuse minute replace weightbase dose approve monotherapy indication eu fda approval company sbla update opdivo dosing include mg infuse week march majority approve indication shorter minute infusion approve indication product indication date development announce new datum cohort checkmate study opdivo plus lowdose october yervoy demonstrate durable clinical benefit firstline treatment patient msih dmmr mcrc crc fda approval opdivo plus lowdose yervoy treatment adult pediatric patient year july old msih dmmr mcrc progress follow treatment fluoropyrimidine oxaliplatin irinotecan announce result interim analysis phase ii checkmate trial evaluate opdivoyervoy patient mcrpc show asymptomatic minimally symptomatic patient disease progress secondgeneration hormone therapy receive chemotherapy cohort mcrpc february median followup month objective response rate additionally patient disease progress taxanebase chemotherapy cohort median followup month objective response rate announce fouryear datum phase iii checkmate clinical trial continue demonstrate october durable longterm survival benefit firstline combination opdivoyervoy versus yervoy melanoma patient advance melanoma approval japan opdivoyervoy combination chemotherapynaive patient unresectable melanoma announce followup datum evaluate opdivo monotherapy opdivo combination yervoy patient platinumpretreate muc result phase iii checkmate trial show patient muc october receive combination opdivo mgkg plus yervoy mgkg experience high objective response rate compare receive opdivo mgkg plus yervoy mgkg opdivo announce voluntary withdrawal company sbla opdivo plus lowdose yervoy treatment january firstline advanced nsclc patient tmb great equal mutation megabase datum checkmate available pdufa goal date opdivoyervoy announce update regulatory action chmp eu ongoing review application indication metastatic firstline nsclc opdivo plus lowdose yervoy patient october tmb greater equal mutation megabase chmp request additional information nsclc checkmate include overall survival analysis opdivoyervoy patient tmb mutation megabase announce result phase iii checkmate trial evaluate opdivo plus lowdose june yervoy opdivo plus chemotherapy versus chemotherapy patient firstline nsclc pdl expression squamous nonsquamous tumor histology extend progressionfree survival announce ema validate type ii variation application treatment adult patient firstline metastatic nsclc tmb greater equal mutation megabase announce new result phase iii checkmate study show therapy opdivo plus low february dose yervoy continue demonstrate longterm survival benefit patient previously untreate advanced metastatic rcc announce ec approval opdivo plus lowdose yervoy previously untreated patient january intermediate poorrisk advance rcc rcc august approval japan opdivo plus lowdose yervoy treatment unresectable metastatic rcc announce patientreported outcome datum phase iii checkmate trial intermediate poor june risk patient advance rcc treat opdivo plus lowdose yervoy versus sunitinib twoyear followup period report significant sustained healthrelate quality life improvement fda approval opdivoyervoy combination previously untreated patient intermediate poor april risk advance rcc announce patientreported outcome phase iii checkmate study meet primary sclc november endpoint overall survival opdivoyervoy versus placebo maintenance therapy patient extensivestage sclc completion firstline platinumbase chemotherapy announce finding large realworld datum analysis nvaf patient population age old eliquis nvaf november receive direct oral anticoagulant show eliquis associate low rate stroke systemic embolism major bleed rivaroxaban dabigatran product indication date development receive positive chmp opinion polyarticular jia subcutaneous injection pediatric patient orencia jia january year age fda approval empliciti injection intravenous use combination pomalidomide dexamethasone november treatment adult patient multiple myeloma receive prior therapy include lenalidomide proteasome inhibitor empliciti rrmm announce ema validate company type ii variation application empliciti combination pomalidomide lowdose dexamethasone treatment adult patient multiple myeloma september receive prior therapy include lenalidomide proteasome inhibitor pi demonstrate disease progression therapy announce ec approval sprycel tablet powder oral suspension formulation combination february chemotherapy treatment pediatric patient newly diagnose philadelphia chromosome positive sprycel fda expand indication sprycel include treatment pediatric patient year age old december newly diagnose philadelphia chromosomepositive combination chemotherapy ec expand indication sprycel include treatment child adolescent aged year cml july years chronic phase philadelphia chromosome positive cml include powder oral suspension yervoy melanoma january ec approval advance unresectable metastatic melanoma pediatric patient year age old announce result phase ii study bms oral selective tyk inhibitor deliver tyk inhibitor psoriasis september significant skin clearance patient moderate severe plaque psoriasis special note forwardlooke statement include document incorporate reference write oral statement time time contain certain forward look statement meaning section security act amend section e exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base historical performance current expectation projection future financial result goal plan objective involve inherent risk assumption uncertainty include internal external factor delay divert change year cause future financial result goal plan objective differ materially express imply statement statement likely relate thing goal plan objective financial position result operation cash flow market position product development product approval sale effort expense performance result current anticipate product pende acquisition celgene outcome contingency legal proceeding financial result forwardlooke statement guarantee include important factor cautionary statement include particularly item risk factor believe cause actual result differ materially forwardlooke statement believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date additional risk currently deem immaterial presently know cause forwardlooke event discuss occur require federal security law undertake obligation release publicly update revision forwardlooke statement result new information future event change circumstance date item quantitative qualitative disclosure market risk expose market risk result change currency exchange rate interest rate certain derivative financial instrument available costeffective basis hedge underlie economic exposure financial instrument include derivative subject counterparty credit risk consider overall fair value measurement derivative financial instrument trading purpose foreign exchange risk significant amount revenue earning cash flow expose change foreign currency rate primary net foreign currency translation exposure euro japanese yen foreign currency forward contract manage risk primarily arise certain intercompany purchase sale transaction expose foreign exchange transaction risk arise nonfunctional currency denominate asset liability earning denominate nonus dollar currency foreign currency forward contract offset exposure designate hedge estimate appreciation underlie currency hedge level dollar variable hold constant decrease fair value foreign exchange forward contract million million december december respectively reduce earning remain life contract expose translation risk nonus dollardenominate net asset nonus dollar borrowing hedge foreign currency exposure net investment certain foreign affiliate designate hedge net investment effective portion foreign exchange gain loss hedge include foreign currency translation component accumulate comprehensive loss net investment decrease equivalent value nonus debt borrowing change remeasurement basis debt subject recognition income change occur additional information refer item financial statement supplementary datanote financial instrument fair value measurement interest rate risk use fixedtofloate interest rate swap contract designate fair value hedge provide appropriate balance fix float rate debt use cross currency interest rate swap contract designate hedge company net investment japan subsidiary fair value contract marketable debt security analyze yearend determine sensitivity interest rate change sensitivity analysis basis point increase shortterm longterm interest rate december december expect adverse impact earning material estimate increase basis point longterm interest rate december december decrease fair value longterm debt million million respectively credit risk monitor investment counterpartie objective minimize concentration credit risk investment policy invest institution meet high credit quality standard establish limit time maturity investment individual counterparty policy require investment enter corporate financial institution meet high credit quality standard use derivative instrument expose credit risk counterparty fails perform fair value derivative instrument contract positive counterparty fails perform collateral require party derivative asset liability position policy diversify derivative counterpartie mitigate overall risk counterparty default additional information refer item financial statement supplementary datanote financial instrument fair value measurement item financial statement supplementary datum bristolmyer squibb company consolidate statement earning dollar million share datum year end december earning net product sale alliance revenue total revenue cost product sell marketing sell administrative research development income net total expense earning income taxis provision income taxis net earning noncontrolle interest net earning attributable bms earning common share basic diluted consolidated statement comprehensive income dollar millions year end december comprehensive income net earning comprehensive lossincome net taxis reclassification earning derivative qualify cash flow hedge pension postretirement benefit availableforsale security foreign currency translation total comprehensive lossincome comprehensive income comprehensive incomeloss attributable noncontrolle interest comprehensive income attributable bms accompany note integral consolidated financial statement bristolmyers squibb company consolidated balance sheet dollar million share share datum december asset current asset cash cash equivalent marketable security receivables inventory prepaid expense total current asset property plant equipment goodwill intangible asset defer income taxis marketable security asset total asset liability current liability shortterm debt obligation account payable accrue liability defer income income taxis payable total current liability defer income income taxis payable pension liability longterm debt total liability commitment contingency equity bristolmyers squibb company shareholder equity prefer stock convertible series par value share authorize million share issue outstanding liquidation value share common stock par value share authorize billion share billion issue capital excess par value stock accumulate comprehensive loss retain earning cost treasury stock million common share million common share total bristolmyer squibb company shareholder equity noncontrolle interest total equity total liability equity accompany note integral consolidated financial statement bristolmyers squibb company consolidate statement cash flow dollar million year end december cash flow operating activity net earning adjustment reconcile net earning net cash provide operating activity depreciation amortization net defer income taxis stockbase compensation impairment charge pension settlement amortization divestiture gain royalty asset acquisition charge lossgain equity investment adjustment change operate asset liability receivable inventory account payable deferred income income taxis payable net cash provide operating activity cash flow invest activity sale maturity marketable security purchase marketable security capital expenditure divestiture proceed acquisition payment net cash inprovide investing activity cash flow financing activity shortterm debt obligation net issuance longterm debt repayment longterm debt repurchase common stock dividend net cash financing activity effect exchange rate cash cash equivalent increase cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral consolidated financial statement note accounting policy recently issue accounting standard basis consolidation consolidate financial statement prepare conformity gaap include account bristolmyer squibb company control majorityowned subsidiary certain variable interest entity intercompany balance transaction eliminate material subsequent event evaluate disclose report issuance date refer summary abbreviate term end term document alliance license arrangement assess determine term provide economic control entity require consolidation entity entity control mean majority voting interest refer variable interest entity consolidate bms power direct activity variable interest entity significantly impact economic performance obligation absorb loss right receive benefit potentially significant entity business segment information bms operate single segment engage discovery development licensing manufacturing marketing distribution sale innovative medicine help patient prevail disease global research development organization supply chain organization responsible discovery development manufacturing supply product regional commercial organization market distribute sell product business support global corporate staff function determination single segment consistent financial information regularly review chief executive officer purpose evaluate performance allocate resource set incentive compensation target planning forecast future period information product regional revenue note revenue use estimate judgment preparation financial statement require use management estimate judgment assumption significant assumption estimate determine fair value potential impairment intangible asset sale rebate return accrual legal contingency income taxis pension postretirement benefit actual result differ estimate result reclassification certain prior period amount reclassify conform current period presentation lossgain equity investment previously present impairment charge adjustment consolidated statement cash flow present separately revenue recognition effective january adopt asc modify retrospective method refer note revenue detailed discussion accounting policy relate revenue recognition include defer revenue royalty refer note alliance detail alliance income taxis provision income taxis include income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis asset liability adjust change tax rate tax law change enact valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment tax benefit recognize uncertain tax position likely tax position sustain examination tax authority base technical merit position tax benefit recognize financial statement particular tax position base large benefit likely realize settlement cash cash equivalent cash cash equivalent include bank deposit time deposit commercial paper money market fund cash equivalent consist highly liquid investment original maturity month time purchase recognize cost approximate fair value marketable debt security marketable debt security classify availableforsale date purchase report fair value fair value determine base observable market quote valuation model assessment counterparty credit worthiness credit default risk underlie security overall capital market liquidity marketable debt security review impairment assess decline market value investment carry value temporary consider intent ability retain investment period time sufficient allow anticipated recovery market value duration extent market value cost investee financial condition investment equity security investments equity security readily determinable fair value record fair value change fair value record income net investment equity security readily determinable fair value record cost minus impairment plus minus change estimate fair value result observable price change orderly transaction identical similar investment issuer change estimate fair value investment equity security readily determinable fair value record income net investment own company account equity method accounting ability exercise significant influence operate financial decision investee maintain share net income loss equity investment account equity method include income net investment equity security readily determinable fair value investment equity account equity method assess potential impairment quarterly basis base qualitative factor inventory valuation inventory state low average cost market property plant equipment depreciation expenditure addition renewal improvement capitalize cost depreciation compute straightline method base estimate useful life relate asset range year building year machinery equipment fixture current fact circumstance periodically evaluate determine carry value depreciable asset hold recoverable circumstance exist estimate undiscounted future cash flow generate longlived asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique unobservable fair value input discount value estimate future cash flow capitalize software eligible cost obtain internal use software capitalize amortize estimate useful life software acquisition business acquire consolidate obtain control fair value asset acquire liability assume recognize date acquisition excess purchase price estimate fair value net asset acquire recognize goodwill business acquisition cost expense incur contingent consideration potential development regulatory approval salesbase milestone salesbase royalty include purchase price business combination exclude asset acquisition amount allocate lead investigational compound asset acquisition expense date acquisition goodwill acquire inprocess research development intangible asset fair value acquire intangible asset typically determine incomebased approach refer excess earning method utilize level fair value input market participant valuation assume global view consider potential jurisdiction indication base discount aftertax cash flow projection risk adjust estimate probability technical regulatory success iprd finitelive intangible asset include license develop technology right iprd project reach commercialization amortize straightline basis estimate useful life estimate useful life determine consider period asset expect contribute future cash flow goodwill tested annually impairment assess qualitative factor perform quantitative analysis determine likely fair value net asset carry amount example qualitative factor assess include share price financial performance compare budget longterm financial plan macroeconomic industry market condition substantial excess fair value carry value net asset annual impairment test perform prior year relevant factor assess individually aggregate iprd test impairment annual basis frequently event occur circumstance change indicate potential reduction fair value asset carry value impairment charge recognize extent carry value iprd determine exceed fair value finitelive intangible asset test impairment fact circumstance suggest carry value asset recoverable carrying value exceed project undiscounted pretax cash flow intangible asset impairment loss equal excess carrying value estimate fair value discount aftertax cash flow recognize restructure restructuring charge recognize result action streamline operation reduce number facility estimate impact restructuring plan include future termination benefit exit cost require judgment actual result vary estimate contingency loss contingency legal proceeding claim occur government investigation shareholder lawsuit product environmental liability contractual claim tax matter accrual recognize probable liability incur loss reasonably estimate gain contingency include contingent proceed related divestiture recognize realize legal fee expense incurred advertising product promotion cost advertising product promotion cost expense incurred advertising product promotion cost include marketing sell administrative expense million million million foreign currency translation foreign subsidiary earning translate dollar average exchange rate net asset foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate recognize comprehensive lossincome research development research development cost expense incur clinical study cost accrue service period specify contract adjust necessary base ongoing review level effort cost actually incur research development cost present net reimbursement alliance partner upfront contingent development milestone payment asset acquisition investigational compound include research development expense alternative future use cash flow payment license asset acquisition investigational compound include operating activity outlicense proceed payment acquisition ownership interest legal entity include acquisition meet accounting definition business include investing activity divestiture proceed royalty consideration receive subsequent relate sale asset business adjustment reflect operating activity include divestiture gain loss relate royalty asset acquisition charge gain loss equity investment gain loss debt redemption recently adopt accounting standard revenue contract customer amend guidance revenue recognition adopt quarter modify retrospective method cumulative effect change recognize retain earning new guidance refer asc require entity recognize revenue expect entitle transfer promise good service customer replace exist revenue recognition standard gaap fivestep model utilize achieve core principle identify customer contract identify contract performance obligation determine transaction price allocate transaction price performance obligation recognize revenue performance obligation satisfied timing recognize revenue typical net product sale customer significantly change transaction price long require fix determinable certain variable consideration recognize prior occurrence resolution contingent event result certain revenue previously defer prior standard transaction price fix determinable account variable consideration recognize early provide term sufficient reliably estimate ultimate price expect realize estimate future royalty contingent fee relate certain arrangement recognize prior party sale event occurring extent probable significant reversal estimate cumulative revenue occur new guidance pertaining separation licensing right relate fee recognition significantly change timing recognize revenue exist alliance arrangement currently generate revenue timing royalty salesbase milestone form contingent consideration result divestiture business royaltie salesbase milestone license arrangement change cumulative effect accounting change result recognize contract asset million million increase retain earning net tax cumulative effect primarily attribute royalty licensing right reacquire alliance partner expect receive future eligible licensing exclusion result new guidance cumulative effect adjustment revenue approximately million low compare report previous guidance refer note revenue information gain loss derecognition nonfinancial asset amend guidance gain loss derecognition nonfinancial asset asc adopt quarter modify retrospective method amendment clarify scope asset derecognition guidance add guidance partial sale nonfinancial asset clarify recognize gain loss transfer nonfinancial asset contract noncustomer certain transaction sale transfer product right constitute business require account similar asc include potential recognition variable consideration amend guidance result early recognition variable consideration depend fact circumstance transaction cumulative effect accounting change result recognize contract asset million million increase retain earning net tax cumulative effect primarily attribute royalty termination fee licensing right reacquire party expect receive future eligible licensing exclusion result new guidance cumulative effect adjustment income net approximately million low compare report previous guidance presentation net periodic pension postretirement benefit amend guidance require net periodic benefit component define benefit pension postretirement plan service cost record outside income operation income adopt quarter retrospective basis cost product sell marketing sell administrative research development expense increase aggregate correspond offset income net adjust amount adoption new guidance follow year end december dollar million report adjust report adjust cost product sell marketing sell administrative research development income net definition business amend guidance revise definition business adopt prospectively quarter amendment provide initial screen substantially fair value gross asset acquire disposed concentrated single identifiable asset group similar identifiable asset integrate set asset activity represent business screen meet set include input substantive process significantly contribute ability create output set represent business amendment narrow definition term output require transfer organize work force output exist amend guidance result transaction account asset future impact result operation dependent individual fact circumstance transaction recognition measurement financial asset liability amend guidance recognition measurement presentation disclosure financial instrument adopt modify retrospective method quarter new guidance require fair value adjustment equity investment readily determinable fair value report earning new guidance require qualitative impairment assessment equity investment readily determinable fair value base observable price change charge earning impairment exist cumulative effect accounting change result million reduction comprehensive lossincome correspond million increase retain earning net tax refer note income net information impact result operation accounting hedging activity amend guidance derivative hedge adopt modify retrospective method quarter amend guidance revise expand item eligible hedge accounting simplifie hedge effectiveness testing change time recognition presentation certain hedge item certain disclosure requirement modify hedging activity prospective basis adoption amend standard material impact company result operation reclassification certain tax effect accumulate comprehensive income amend guidance reclassification certain tax effect accumulate comprehensive income adopt prospectively fourth quarter new guidance permit reclassification income tax effect amount record accumulate comprehensive income impact tax cut job act retain earning company record cumulative effect adjustment increase accumulate comprehensive loss million corresponding increase retain earning collaborative arrangement amend guidance clarify interaction asc revenue contract customer asc collaborative arrangement adopt retrospectively quarter amend guidance clarifie certain transaction collaborative arrangement participant account present revenue asc adoption amend guidance impact company result operation recently issue accounting standard adopt lease february fasb issue amend guidance lease accounting amend guidance require recognition rightofuse asset lease liability initially measure present value future lease payment lease term long month amend guidance adopt january modify retrospective approach company assessment amend guidance substantially complete include implementation leasing software system procure party vendor gather lease information datum assessment reasonable certainty exercise renewal termination option evaluation change enhancement process internal control base assessment intend elect package practical expedient adoption apply shortterm lease recognition exemption lease term month include option purchase underlie asset reasonably certain exercise apply portfolio approach discount real property lease liability company incremental borrowing rate real property lease provide implicit rate lease term vary base nature operation market dynamic country lease facility classify operating lease remain lease term year comprise approximately total lease obligation discount value approximately million december amend guidance expect materially impact company result operation recognition rightofuse asset lease liability sublease income material company result operation cumulative effect accounting change expect material company result operation financial instrument measurement credit loss june fasb issue amend guidance measurement credit loss financial instrument entity require use forwardlooke estimate loss model availableforsale debt security credit loss recognize allowance reduction amortize cost guidance effective january early adoption permit modify retrospective approach amend guidance expect materially impact company result operation goodwill impairment testing january fasb issue amend guidance simplifie recognition measurement goodwill impairment loss eliminate step quantitative impairment test result impairment charge require report unit carry exceed fair value allocate goodwill guidance effective prospective basis january early adoption permit interim annual goodwill impairment test perform january amend guidance expect materially impact company result operation note revenue follow table summarize disaggregation revenue nature year end december dollar million net product sale alliance revenues revenues total revenue net product sale represent company total revenue year end december product sell principally wholesaler distributor less extent directly retailer hospital clinic government agency pharmacie customer order generally fulfil day receipt result minimal order backlog contractual performance obligation usually limit transfer control product customer transfer occur shipment receipt product certain nonus country consider customer obtain legal title product company obtain right payment point customer able direct use obtain substantially remain benefit product gross revenue large pharmaceutical wholesaler percentage global gross revenue follow mckesson corporation amerisourcebergen corporation cardinal health inc wholesaler initially invoice contractual list price payment term typically day base customary practice country exception certain biologic product include opdivo yervoy empliciti day day revenue reduce wholesaler list price time recognition expect chargeback discount rebate sale allowance product return refer gtn adjustment reduction attribute commercial arrangement manage healthcare organization government program medicare medicaid b drug pricing program contain pricing implication mandatory discount pricing protection wholesaler list price discount medicare beneficiarie coverage gap addition nonus government program include different pricing scheme cost cap volume discount outcome base pricing pricing clawback determine sale individual company aggregation company participate specific market chargeback cash discount reflect reduction receivables settle issuance credit customer typically month rebate discount adjustment include medicaid medicare reflect liability settle cash payment customer typically time period range month year significant judgment require estimate gtn adjustment consider legal interpretation applicable law regulation historical experience payer channel mix current contract price applicable program unbilled claim processing time lag inventory level distribution channel follow table summarize gtn adjustment year end december dollar millions gross product sale gtn adjustmentsa chargeback cash discount medicaid medicare rebate rebate return discount adjustment total gtn adjustment net product sale include adjustment provision product sale prior period result change estimate million million million year end december respectively alliance revenue consist primarily amount relate collaboration outlicense arrangement arrangement evaluate represent contract scope revenue recognition guidance entirety contain aspect scope guidance directly reference base application guidance relate derecognition nonfinancial asset asc performance obligation identify separate party benefit directly right good service readily available resource right good service highly interdependent interrelate transaction price arrangement include fix upfront amount variable consideration contingent development regulatory milestone salesbase milestone royalty likely method estimate contingent development regulatory salesbase milestone ultimate outcome binary nature expect value method estimate royalty broad range potential outcome exist instance royalty relate license variable consideration include transaction price extent significant reversal cumulative revenue recognize probable occurring uncertainty associate variable consideration subsequently resolve significant judgment require estimating variable consideration recognize assess factor outside bmss influence likelihood regulatory success limited availability party information expect duration time resolution lack relevant past experience historical practice offering fee concession large number broad range possible amount extent arrangement include multiple performance obligation separable transaction price assign distinct performance obligation reflective relative standalone selling price recognize point time transfer control type outlicense arrangement typically utilize arrangement outlicense intellectual property party performance obligation arrangement include license additional performance obligation supply product request party collaboration arrangement include transfer license party jointly develop commercialize product outlicense arrangement consist single performance obligation satisfy execution agreement development commercialization right transfer party upfront fee recognize immediately include income net contingent development regulatory milestone amount assess period likelihood achievement typically constrain recognize uncertainty subsequently resolve milestone include income net salesbase milestone royalty recognize milestone achieve subsequent sale occur salesbased milestone include income net royalty include alliance revenue certain outlicensing arrangement include contingent performance obligation supply commercial product party request license supply obligation account separate performance obligation consider distinct party benefit license supply resource readily available obligation separately identifiable obligation contract accordance revenue recognition guidance consider standalone selling price situation upfront fee contingent development regulatory milestone amount salesbase milestone royalty allocate license recognize manner describe consideration supply obligation usually base stipulate costplus margin contractual term represent standalone selling price supply consideration recognize point time transfer control product party include alliance revenue fee allocation license supply represent consideration company expect entitle satisfaction separate performance obligation collaboration arrangement unique nature party active participant operating activity expose significant risk reward depend commercial success activity performance obligation inherent arrangement include transfer certain development commercialization right ongoing development commercialization service product supply obligation certain product supply obligation consider distinct account separate performance obligation similar manner discuss performance obligation consider distinct combine single performance obligation transfer right highly integrate interrelated obligation jointly develop commercialize product party result upfront fee recognize ratably time expect period collaboration activity include income net license combine development commercialization obligation contingent development regulatory milestone long constrain recognize similar manner prospective basis royalty profit sharing recognize underlie sale profit occur include alliance revenue refer note alliance information follow table summarize disaggregation revenue product region year end december dollar millions prioritize brand opdivo eliquis orencia sprycel yervoy empliciti establish brand baraclude reyataz franchise sustiva franchise hepatitis c franchise brand total revenues united states europe rest world othera total revenue revenue include royalty alliancerelate revenue product sell regional commercial organization follow table summarize contract asset december january dollar millions december january prepay expense asset total contract asset contract asset primarily estimate future royalty termination fee eligible licensing exclusion recognize adoption asc asc contract asset reduce receivable increase period underlie sale occur contingent development regulatory milestone outlicense arrangement billion constrain recognize consider likelihood significant reversal cumulative revenue occur cumulative catchup adjustment revenue affect contract asset contract liability material year end december revenue recognize performance obligation satisfy prior period million year end december consist primarily royalty outlicense arrangement revise estimate gtn adjustment relate prior period sale sale commission incremental cost obtain customer contract expense incur amortization period year note alliance bms enter collaboration arrangement party development commercialization certain product arrangement unique nature party active participant operating activity collaboration expose significant risk reward depend commercial success activity bms inlicense intellectual property own party outlicense intellectual property party arrangement typically include research development manufacturing andor commercial activity cover single investigational compound commercial product multiple compound andor product life cycle stage right obligation party global limited geographic region refer collaboration alliance partner alliance partner common activity bms alliance partner present result operation follow bms principal end customer sale product sale include net product sale bms alliance partner principal end customer sale bms contractual share thirdparty sale andor royalty income include alliance revenues sale commercial product consider bms ongoing major central operation refer note revenue information recognition criterion amount payable bms alliance partner principal end customer sale supply commercial product include alliance revenues sale commercial product consider bms ongoing major central operation profit share royalty salesbase fee payable bms alliance partner include cost product sell incur cost reimbursement party recognize incur include cost product sell marketing sell administrative expense research development expense base underlying nature relate activity subject reimbursement upfront contingent development approval milestone payable bms alliance partner investigational compound commercial product defer amortize expect period bms development copromotion obligation market exclusivity period period relate compound product expect contribute future cash flow amortization present consistent nature payment arrangement example amount receive investigational compound present income net activity perform time relate sale commercial product include bmss ongoing major central operation amount receive commercial product present alliance revenue sale commercial product consider bmss ongoing major central operation upfront contingent approval milestone payable bms alliance partner commercial product capitalize amortize short contractual term period relate product expect contribute future cash flow amortization include cost product sell upfront contingent milestone payable bms alliance partner prior regulatory approval expense incur include research development expense royalty contingent consideration payable bms alliance partner relate divestiture business include income net earn payment bms alliance partner present cash flow operating activity describe select financial information pertain alliance follow include net product sale bms principal thirdparty customer sale product subject alliance expense summarize include amount attribute activity product alliance payment alliance partner relate amortization payment defer capitalize certain prior period amount include revise exclude amount arrangement long meet criterion collaboration arrangement year end december dollar millions revenue alliance net product sale alliance revenue total revenue payment tofrom alliance partner cost product sell marketing sell administrative research development income net select alliance balance sheet information december dollar million receivable alliance partner account payable alliance partner defer income alliancesa include unamortized upfront milestone payment specific information pertain significant alliance discuss include nature purpose significant right obligation party specific accounting policy election income statement classification amount attributable payment party pfizer bms pfizer jointly develop commercialize eliquis anticoagulant discover bms pfizer fund development cost depend study profit loss share equally global basis certain country pfizer commercialize eliquis pay bms sale base fee coexclusive license right grant pfizer exchange upfront payment potential milestone payment party assume certain obligation actively participate joint executive committee operating committee joint responsibility research development distribution sale marketing activity alliance resource infrastructure bms pfizer manufacture product alliance bms principal end customer product sale significant country europe canada australia china japan south korea bms transfer commercialization right pfizer certain small country order simplify operation transfer country bms supply product pfizer cost plus percentage net sale price endcustomer record transfer control product pfizer company allocate consideration right transfer pfizer right sell separately bms party pfizer receive benefit deliver right fulfillment ongoing obligation bms alliance agreement global alliance treat single unit accounting upfront proceed subsequent contingent milestone proceed amortize expect period bms co promotion obligation market exclusivity period bms receive million nonrefundable upfront milestone licensing payment relate eliquis december amortization eliquis defer income include income net eliquis commercial product commencement alliance summarize financial information relate alliance follow year end december dollar millions revenue pfizer alliance net product sale alliance revenue total revenue payment tofrom pfizer cost product sell profit sharing income net amortization defer income select alliance balance sheet information december dollar million receivables account payable deferred income otsuka bms otsuka copromote sprycel eu party actively participate governance committee bms control decision make bms responsible development manufacture product principal end customer product sale fee pay otsuka base net sale level oncology territory japan eu equate million billion annual net sale plus net sale excess billion summarize financial information relate alliance follow year end december dollar million revenue otsuka alliance net product sale oncology territory payment otsuka cost product sell oncology fee bms worldwide commercialization agreement otsuka codevelop copromote abilify portion agreement expire april eu portion expire june country bms exclusive right sell abilify expiration occur countrybycountry basis expiration canada january ono bms ono jointly develop commercialize opdivo yervoy bms investigational compound japan south korea taiwan bms responsible supply product profit loss development cost share equally combination therapy involve compound party share activity involve party compound bms ono jointly develop commercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulation jointly promote party assign customer account bms responsible product supply copromotion fee pay sale partys assign customer ono grant bms exclusive license development commercialization ono onos prostaglandin e receptor antagonist bms acquire worldwide right japan south korea taiwan add exist collaboration china asean country ono retain exclusive right bms pay million ono include research development expense ono eligible receive subsequent clinical regulatory salesbase milestone payment million royalty country bms exclusive licensing right bms provide ono right accept nktr alliance completion phase clinical study opdivo nktr ono territory right exercise ono partially reimburse bms development cost incur study share certain future development cost contingent milestone payment profit loss collaboration nektar summarize financial information relate alliance follow year end december dollar millions revenue ono alliance net product sale alliance revenue total revenue bms principal end customer product sale exclusive right develop manufacture commercialize opdivo worldwide japan south korea taiwan ono entitle receive royalty north america territory exclude country list subject customary adjustment gilead bms gilead operate joint venture europe develop commercialize combination product name atripla combine bms sustiva gilead truvada joint venture consolidate gilead principal end customer product sale bms receive percentage end customer sale record alliance revenue joint venture continue party terminate arrangement patent expire allow market exclusivity atripla prior bms gilead operate joint venture canada atripla terminate follow launch generic version sustiva thirdparty result deferred income alliance receivables attribute sustiva product hold joint venture december reduce million reflect posttermination sell price bms entitle fee equal atripla net sale multiply ratio difference average net selling price atripla truvada atripla average net selling price fee reduce atripla net sale multiply ratio describe bms supply sustiva cost plus markup gilead threeyear period terminate supply agreement notice period summarize financial information relate alliance follow year end december dollar million revenue gilead alliance alliance revenues equity net loss affiliate nektar bms nektar commence worldwide license collaboration development commercialization nktr nektar investigational immunostimulatory therapy design selectively expand specific cancerfighting cell natural killer cell directly tumor microenvironment opdivo nktr combination therapy currently phase ii clinical study multiple cancer indication phase iii clinical study melanoma rcc joint development plan agree party contemplate development indication tumor type party responsible supply product bms share development cost associate therapy comprise bms medicine combination nktr subject certain cost cap nektar party jointly commercialize therapy subject regulatory approval bms share global nktr profit loss subject certain annual loss cap nektar bm pay nektar billion right discuss million share nektar common stock represent ownership interest bms equity ownership subject certain lockup standstill voting provision fiveyear period upfront payment allocate equity investment million consider nektar stock price date close current limitation trading security remain billion payment allocate right discuss include research development expense second quarter bms pay billion achievement contingent development regulatory salesbase milestone life alliance period research development expense payable agreement nektar million year end december abbvie bms abbvie jointly develop commercialize empliciti humanize monoclonal antibody treatment multiple myeloma party participate development commercialization committee bms final decision make authority abbvie fund global development cost bms solely responsible supply distribution sale marketing activity principal end customer product sale abbvie share profit loss pay tiere royalty outside abbvie entitle receive additional million certain regulatory event occur million certain sale threshold achieve agreement terminate immediately bm party material breach subsequent notice period summarize financial information relate alliance follow year end december dollar millions revenues abbvie alliance net product sale payment abbvie cost product sell profit sharing note acquisition divestiture license arrangement acquisition acquisition evaluate determine business asset group asset follow transaction account asset acquisition determined business term define asc primarily significant process acquire result amount allocate lead investigational compound expense capitalize consideration transaction execution year allocate follow contingent dollar millions year upfront payment rd expense defer tax assetsa consideration ifmb cormorant padlock relate net operating loss tax credit carryforward b include million certain negotiation right collaborate license acquire nlrp antagonist program newly form entity establish shareholder ifm ifm bms acquire outstanding share ifm private biotechnology company focus develop therapy modulate novel target innate immune system treat cancer autoimmunity inflammatory disease acquisition provide bms right ifm preclinical sting nlrp agonist program focus enhance innate immune response treat cancer contingent consideration include development regulatory salesbase milestone payment million include research development expense follow commencement phase clinical study bms pay million additional contingent milestone subsequent product select ifm preclinical sting nlrp agonist program include contingent consideration table cormorant bms acquire outstanding share cormorant private pharmaceutical company focus develop therapy cancer rare disease acquisition provide bms right cormorant lead candidate humaxil phase iii monoclonal antibody represent potentially complementary io mechanism action tcell direct antibodie costimulatory molecule contingent consideration include development regulatory milestone payment million include research development expense conclusion month reversion option period padlock bms acquire outstanding share padlock private biotechnology company dedicate create new medicine treat destructive autoimmune disease acquisition provide bms right padlock pad inhibitor discovery program focus development potentially transformational treatment approach patients ra padlock pad discovery program additional utility treat systemic lupus erythematosus autoimmune disease contingent consideration include development regulatory milestone payment cardioxyl bms acquire outstanding share cardioxyl private biotechnology company focus discovery development novel therapeutic agent cardiovascular disease acquisition provide bms right cxl nitroxyl prodrug phase ii development acute decompensate heart failure contingent consideration include development regulatory salesbase milestone payment million include research development expense follow commencement phase ii clinical study flexus bms acquire outstanding share flexus private biotechnology company focus discovery development novel anticancer therapeutic acquisition provide bms right f preclinical small molecule idoinhibitor target immunotherapy addition bms acquire flexus idotdo discovery program include idoselective idotdo dual tdoselective compound contingent consideration include development regulatory milestone payment million million include research development expense respectively follow commencement phase phase ii phase iii clinical study divestiture follow table summarize proceed gain royalty income result divestiture revenue pretax earning relate divestiture asset heldforsale material period present exclude divestiture gain proceedsa divestiture gain royalty income dollar millions diabete business erbitux business manufacturing operation plavix avaproavalide investigational hiv business otc business mature brand include royalty receive subsequent relate sale asset business diabete business february bms astrazeneca terminate diabetes business alliance agreement bms sell astrazeneca substantially diabete business comprise alliance divestiture include share amylin result transfer ohio manufacturing facility intellectual property relate onglyza farxiga include bms interest outlicensing agreement onglyza japan purchase bmss manufacturing facility locate mount vernon indiana consideration transaction include billion payment closing contingent regulatory salesbase milestone payment billion include million relate approval milestone million relate salesbased milestone payable tiere royalty payment range base net sale payment million certain asset transfer astrazeneca astrazeneca pay bms require product supply price approximating product cost negotiate transitional service fee consideration allocate development supply agreement amortize applicable service period amortization defer income attribute development agreement end december million include income net sale service consider bmss ongoing major central operation amortization defer income attribute supply agreement end december record alliance revenues revenues attribute supply agreement include alliance revenues material royalty present income net million million million contingent consideration million receive result additional gain achievement regulatory approval milestone september bms transfer percentage future royalty right amylin net product sale cppib transfer right represent approximately potential future royalty bms entitle exchange transfer bms receive additional tieredbase royalty amylin net product sale cppib royalty present income net million million million november bm transfer percentage future royalty right portion onglyza farxiga net product sale royalty pharma transfer right represent approximately potential future royalty bms entitle product exchange transfer bms receive additional tieredbase royalty onglyza farxiga net product sale royalty pharma royalty present income net million erbitux business bms commercialization agreement lilly lillys subsidiary imclone codevelopment promotion erbitux canada japan bms principal end customer product sale north america pay lilly distribution fee erbitux net sale north america plus share certain royalty pay lilly october bms transfer right erbitux north america lilly exchange tiere salesbase royalty september include income net royalty earn million million million bm transfer cocommercialization right japan merck kgaa exchange salesbase royalty include income net earn royalty earn million million result adoption asc quarter estimate future royalty result transfer right merck kgaa record cumulative effect adjustment retain earning subsequent change estimate record income net refer note accounting policy recently issue accounting standard detail manufacturing operation bms sell small molecule active pharmaceutical ingredient manufacturing operation sword ireland sk biotek approximately million subject certain adjustment initial proceed million receive quarter transaction account sale business divestiture include transfer facility majority employee site inventory certain thirdparty contract manufacturing obligation asset reduce estimate relative fair value consider purchase price result impairment charge million include cost product sell sk biotek provide certain manufacturing service bms plavix avaproavalide sanofi reacquire bms codevelopment cocommercialization agreement plavix avaproavalide consideration transfer right include quarterly royalty december million terminal payment receive million allocate optout market million allocate bms interest europe asia territory partnership royalty expect receive portion terminal payment allocate optout market reflect contract asset cumulative effect adjustment adoption asc bm fulfil performance obligation million allocate bms partnership interest defer december recognize income net transfer sanofi refer note accounting policy recently issue accounting standard detail royalty earn sanofi territory cover americas australia optout market present alliance revenue aggregate million million million royalty attribute territory cover europe asia earn territory partnership pay bms include equity net income affiliate amount million million million investigational hiv business bm sell investigational hiv medicine business consist number rd program different stage discovery development viiv healthcare bm receive million entitle receive viiv healthcare contingent development regulatory milestone payment billion salesbase milestone payment billion future tiere royalty bms earn transitional fee million million certain rd service respectively otc business bm sell reckitt otc business contain brand sell primarily mexico brazil million gain million include trademark inventory certain asset exclusively relate product manufacturing facility locate mexico primarily dedicated product mature brand divestiture include brand sell cheplapharm result proceed million divestiture gain million asset heldforsale bms agree sell upsa consumer health business billion transaction expect close second quarter account sale business business account heldforsale december accordingly asset million reclassify asset heldforsale include prepaid expense include million receivable million inventory million property plant equipment million goodwill additionally liabilitie million reclassify liability relate asset heldforsale include accrue liability include million accrue liability million account payable million defer tax liability million liability december bms agree sell rd facility wallingford connecticut transaction close account sale asset facility account heldforsale december reduce estimate relative fair value result impairment charge million include research development expense licensing arrangement promedior bms purchase warrant give bms exclusive right acquire promedior biotechnology company lead asset prm develop treatment ipf mf warrant exercisable delivery phase ii datum follow ipf mf phase ii clinical study direct promedior upfront payment allocate warrant million include research development expense remain million million upfront payment allocate promedior obligation complete phase ii study amortize expect period phase ii study allocation determine level input bms notify promedior exercise warrant purchase outstanding share promedior halozyme bms halozyme enter global collaboration license agreement develop subcutaneously administer bms io medicine halozyme enhanze drugdelivery technology technology allow rapid delivery large volume injectable medication subcutaneous delivery bms pay million halozyme access technology include research development expense bms designate multiple io target include pd develop enhanze technology option select additional target year effective date maximum target bms pay contingent development regulatory salesbase milestone million achieve nominate collaboration target additional milestone payment combination product future royalty sale product enhanze technology cytomx bms expand strategic collaboration cytomx discover novel therapy cytomxs proprietary probody platform original collaboration discover develop commercialize probody therapeutic bms select oncology target include ctla pursuant expand agreement cytomx grant bms exclusive worldwide right develop commercialize probody therapeutic additional target bms pay cytomx million right initial target expense rd prior bms pay million cytomx access additional target include research development expense bms reimburse cytomx certain research cost collaboration period pay contingent development regulatory salesbase milestone million achieve collaboration target future royalty biogen bms outlicense biogen exclusive right develop commercialize bms antietau compound development progressive supranuclear palsy biogen pay million bms include income net bms entitle contingent development regulatory salesbase milestone payment million achieve future royalty bms originally acquire right compound acquisition ipierian biogen assume bmss remain obligation stockholder ipierian roche bms outlicense roche exclusive right develop commercialize bms antimyostatin adnectin development duchenne muscular dystrophy roche pay million bms include income net bms entitle contingent development regulatory milestone payment million achieve future royalty nitto denko bms nitto denko enter exclusive worldwide license agreement grant bms right develop commercialize nitto denko investigational sirna molecule target hsp vitamin contain formulation include nitto denko lead asset ndls currently phase ii study treatment advance liver fibrosis bms pay million nitto denko include research development expense bms pay contingent development regulatory salesbase milestone million achieve future royalty agreement grant bms option receive exclusive license hsp sirnas vitamin contain formulation treatment lung fibrosis organ fibrosis fstar bms acquire exclusive option purchase fstar lead asset fs antiher antibody fragment development treatment breast gastric cancer welldefine population herpositive patient bms discontinue development fs exercise option result iprd charge million include research development expense attribute noncontrolle interest note income net year end december dollar million interest expense investment income lossgain equity investment provision restructure litigation settlement equity net income affiliate divestiture gain royalty license income transition service fee pension postretirement intangible asset impairment loss debt redemption income net lossgain equity investment include fair value adjustment million relate company equity investment nektar litigation settlement include million bms share patentinfringement settlement relate merck pd antibody keytruda royalty licensing income include royalty result business divestiture intellectual property legal settlement upfront licensing fee include million biogen roche transition service fee primarily relate divestiture diabete investigational hiv medicine business note restructure october company announce restructure plan evolve streamline operating model expect incur charge connection employee workforce reduction early site exit majority charge expect incur range billion billion consist employee termination benefit cost contract termination cost accelerate depreciation impairment charge site exit cost cash outlay connection action expect approximately total charge charge approximately billion recognize action announcement include impairment charge small molecule manufacturing operation sword ireland restructuring charge recognize meet certain criterion include finalization commit plan reliable estimate discussion local work council certain market restructure charge addition action recognize prior primarily relate specialty care transformation initiative design create simplify organization function geographic market addition accelerate depreciation charge incur connection expect early exit small molecule manufacturing site cruiserath ireland rd facility wallingford connecticut refer note acquisition divestiture license arrangement information employee workforce reduction approximately follow table summarize charge activity relate restructuring action year end december dollar million employee termination cost termination cost provision restructuring accelerate depreciation asset impairment shutdown cost total charge year end december dollar million cost product sell marketing sell administrative research development income net total charge year end december dollar million liability january charge change estimate provision restructure foreign currency translation payment liability december note income taxis provisionbenefit income taxis consist year end december dollar millions current nonus total current defer nonus total defer total provision effective tax rate reconciliation effective tax rate statutory federal income tax rate earning income taxis dollar million earning income taxis nonus total statutory rate deem repatriation transition tax defer tax remeasurement global intangible low tax income gilti foreign tax effect certain operation ireland puerto rico switzerland federal valuation allowance federal state foreign contingent tax matter federal research base credit goodwill allocate divestiture brand prescription drug fee nondeductible rd charge puerto rico excise tax domestic manufacturing deduction state local taxis net valuation allowance foreign new tax reform legislation enact december know tax cut job act act act move worldwide tax system quasiterritorial tax system comprise broad complex change tax code include limited reduce tax rate add deem repatriation transition tax certain foreign earning profit generally eliminate federal income taxis dividend foreign subsidiary include certain income control foreign company taxable income gilti create new minimum tax refer base erosion antiabuse income tax limit certain federal research base credit eliminate domestic manufacturing deduction aspect act effective additional tax expense billion recognize fourth quarter enactment include billion onetime deem repatriation transition tax previously untaxe post foreign earning profit include related tax reserve earning effectively tax rate extent specify foreign corporation hold cash certain asset rate remain earning profit remain additional tax expense include adjustment measure net defer tax asset new tax rate provisional tax charge deem repatriation transition tax include related tax reserve staff accounting bulletin reduce million accounting reduction defer tax asset tax rate complete december tax charge deem repatriation transition tax complete december prior enactment act earning certain manufacturing operation low tax jurisdiction switzerland ireland puerto rico indefinitely reinveste result transition tax act company long indefinitely reinveste respect undistribute earning foreign subsidiary provide defer tax liability foreign state income withholding tax apply company remain indefinitely reinveste respect financial statement basis excess tax basis foreign subsidiary determination defer tax liability respect basis difference practicable bms operate favorable tax grant puerto rico schedule expire prior valuation allowance set result nektar equity investment fair value loss consider limited capital loss federal state foreign contingent tax matter include million tax benefit respect lapse statute goodwill allocate business divestiture brand prescription drug fee deductible tax purpose rd charge primarily acquisition relate milestone payment shareholder deductible tax purpose include cormorant ifm flexus cardioxyl ifm flexus padlock cormorant puerto rico impose excise tax gross company purchase price good sell manufacturer puerto rico excise tax recognize cost product sell intraentity sale occur income tax purpose excise tax deductible result foreign tax credit generally recognize provision income taxis excise tax incur defer taxis valuation allowance component current noncurrent defer income tax assetsliabilitie follow december dollar millions defer tax asset foreign net operating loss carryforward state net operating loss credit carryforward federal net operating loss credit carryforward defer income milestone payment license fee pension postretirement benefit intercompany profit inventory item foreign defer tax asset sharebase compensation total defer tax asset valuation allowance defer tax asset net valuation allowance defer tax liability depreciation acquire intangible asset goodwill total defer tax liability defer tax asset net recognize deferred income taxis noncurrent income taxis payable noncurrent liability relate asset heldforsale total federal net operating loss carryforward million december carryforward acquire result certain acquisition subject limitation section internal revenue code net operating loss carryforward expire vary amount begin foreign state net operating loss carryforward expire vary amount begin certain amount unlimited life december valuation allowance billion establish follow item billion primarily foreign net operating loss tax credit carryforward million state defer tax asset include net operating loss tax credit carryforward million federal defer tax asset include equity fair value adjustment federal net operating loss carryforward change valuation allowance follow year end december dollar million balance begin year provision utilization foreign currency translation acquisition non rate change balance end year income tax payment million million billion business conduct country world subject tax numerous jurisdiction significant number tax return file subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report require year resolve liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense deem repatriation transition tax liability represent reasonable provision taxis ultimately expect pay need adjusted time information know effect change estimate related contingent tax liability include effective tax rate reconciliation reconciliation begin end gross unrecognized tax benefit follow year end december dollar million balance begin year gross addition tax position relate current year gross addition tax position relate prior year gross addition tax position assume acquisition gross reduction tax position relate prior year settlement reduction tax position relate lapse statute cumulative translation adjustment balance end year additional information unrecognized tax benefit follow year end december dollar millions unrecognized tax benefit recognize impact effective tax rate accrue interest accrue penalty accrue interest penalty payable unrecognized tax benefit include current noncurrent income taxis payable interest penalty relate unrecognized tax benefit include income tax expense bms currently examination number tax authority propose consider propose material adjustment tax position issue transfer price certain tax credit deductibility certain expense reasonably possible new issue raise tax authority require adjustment unrecognized tax benefit estimate adjustment reasonably time reasonably possible total unrecognized tax benefit december decrease range approximately million million month result settlement certain tax audits event expect change unrecognized tax benefit result payment additional taxis adjustment certain defer taxis andor recognition tax benefit reasonably possible new issue raise tax authority increase unrecognized tax benefit estimate increase reasonably time bms believe adequately provide open tax year tax jurisdiction follow summary major tax jurisdiction tax authority assert additional taxis base tax year currently audit subsequent year likely audit canada france germany italy mexico note earning share year end december amount million share datum net earning attributable bms basic diluted eps calculation weightedaverage common share outstanding basic incremental share attributable sharebased compensation plan weightedaverage common share outstanding diluted earning share basic earning share dilute note financial instrument fair value measurement financial instrument include cash cash equivalent marketable security account receivable payable debt instrument derivative change exchange rate interest rate create exposure market risk certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument qualify cash flow net investment fair value hedge meet certain criterion include effectiveness offset hedge exposure change fair value derivative qualify hedge accounting recognize earning occur derivative financial instrument trading purpose financial instrument subject counterparty credit risk consider overall fair value measurement counterparty credit risk monitor ongoing basis mitigate limiting amount outstanding individual counterparty utilize conventional derivative financial instrument enter agreement counterpartie meet high credit quality standard consolidate financial statement materially impact counterparty fail perform accord term agreement collateral require party derivative asset liability position term agreement fair value measurement fair value financial instrument classify follow category level input utilize unadjusted quote price active market accessible measurement date identical asset liability fair value hierarchy provide high priority level input level input utilize observable price similar instrument quote price identical similar instrument nonactive market additionally certain corporate debt security utilize thirdparty matrix pricing model significant input corroborate market datum substantially term asset equity fix income fund primarily invest publicly trade security value respective nav underlie investment level derivative instrument value libor yield curve credit valuation adjustment observable forward foreign exchange rate report date valuation derivative contract fluctuate considerably volatility underlie foreign currency underlie interest rate drive market condition duration contract level unobservable input little market datum available level financial asset liability december financial asset liability measure fair value recur basis summarize december december dollar million level level level level cash cash equivalent money market security marketable security certificate deposit commercial paper corporate debt security equity investment derivative asset equity investment derivative liability availableforsale security change fair value equity investment include income net adoption asu quarter follow table summarize debt equity security classify availableforsale december december gross unrealize gross unrealized amortize amortize dollar million cost gain loss fair value cost gain loss fair value certificate deposit commercial paper corporate debt security equity investmentsa equity investmentsb total december december dollars million current marketable security noncurrent marketable securitiesc assetsa total include equity investment readily determinable fair value measure fair value option december b include equity fix income fund measure fair value option december refer note accounting policy recently issue accounting standard information c noncurrent marketable security mature year december december equity investment measure fair value exclude table limit partnership equity method investment million december million december equity investment readily determinable fair value million december million december amount include asset adjustment equity investment readily determinable fair value million result observable price change similar security issuer record income net follow table summarize net loss record equity investment readily determinable fair value hold december year end december dollar million net loss recognize net gain recognize equity investment sell net unrealized loss equity investment hold qualifying hedge nonqualifye derivative cash flow hedge foreign currency forward contract hedge certain forecast intercompany inventory purchase sale transaction certain foreign currency transaction fair value contract designate cash flow hedge temporarily report accumulate comprehensive loss include earning hedge item affect earning adoption amend guidance derivative hedge entire change fair value hedge instrument include assessment hedge effectiveness record derivative qualify cash flow hedge component comprehensive lossincome net gain loss foreign currency forward contract expect reclassify net earning primarily include cost product sell month notional outstanding foreign currency forward contract primarily attribute euro billion japanese yen million december earning impact relate discontinued cash flow hedge hedge ineffectiveness significant period present cash flow hedge accounting discontinue forecast transaction long probable occur day originally forecast date hedge long effective assessment determine derivative designate qualifying hedge highly effective offset change cash flow hedge item perform inception quarterly basis foreign currency forward contract designate hedge instrument offset exposure certain foreign currency denominate asset liability earning change fair value derivative recognize earning occur net investment hedge nonus dollar borrowing million billion december designate hedge euro currency exposure net investment certain foreign affiliate borrowing designate net investment hedge recognize long term debt effective portion foreign exchange gain remeasurement euro debt million million respectively loss million record foreign currency translation component accumulate comprehensive loss relate offset longterm debt january bm enter million crosscurrency interest rate swap contract mature december designate hedge japanese yen currency exposure company net investment japan subsidiary contract fair value change record foreign currency translation component comprehensive lossincome relate offset pension liability fair value hedge fix float interest rate swap contract designate fair value hedge interest rate risk management strategy create appropriate balance fix float rate debt contract underlie debt hedge benchmark risk record fair value effective interest rate contract onemonth libor december plus interest rate spread range gain loss result change fair value underlie debt attributable hedge benchmark interest rate risk record interest expense associate offset carry value debt specific term notional swap intend match debt hedge change fair value swap record interest expense associate offset derivative asset liability consolidate balance sheet result net impact earning underlie swap terminate prior maturity fair value adjustment underlie debt amortize reduction interest expense remain term debt follow summarize fair value outstanding derivative december december asseta liabilityb asseta liabilityb dollar million notional fair value notional fair value notional fair value notional fair value derivative designate hedge instrument interest rate swap contract crosscurrency interest rate swap contract foreign currency forward contract derivative designate hedge instrument foreign currency forward contract include prepay expense asset b include accrue liability pension liability follow table summarize financial statement classification gainloss recognize hedging instrument year end december cost income cost income cost income dollar million product sell net product sell net product sell net interest rate swap contract crosscurrency interest rate swap contract foreign currency forward contract follow table summarize effect derivative nonderivative instrument designate hedge instrument comprehensive lossincome year end december dollar million derivative qualify cash flow hedge foreign currency forward contract gainloss recognize comprehensive lossincomea reclassify cost product sell reclassify income net derivative qualify net investment hedge crosscurrency interest rate swap contract loss recognize comprehensive lossincome nonderivative qualify net investment hedge non dollar borrowing gainloss recognize comprehensive lossincome expect reclassify earning month debt obligation shortterm debt obligation include december dollar millions commercial paper nonus shortterm borrowing current portion longterm debt total average commercial paper outstanding million million weightedaverage interest rate respectively maximum commercial paper outstanding million outstanding borrowing december maximum commercial paper outstanding billion million outstanding borrowing december longterm debt current portion longterm debt include december dollar million principal value note note note note note euro note note note euro note note note note note note mature subtotal adjustment principal value fair value interest rate swap contract unamortize basis adjustment swap termination unamortized bond discount issuance cost total current portion longterm debt longterm debt fair value longterm debt billion billion december respectively value level input base quote market price similar debt instrument fair value shortterm borrowing approximate carry value short maturity debt instrument senior unsecured note issue register public offering notes rank equally right payment bms exist future senior unsecured indebtedness redeemable time predetermine redemption price follow table summarize issuance long term debt obligation dollar million principal value note note total proceed net discount defer loan issuance cost forward start interest rate swap contract terminate notional realize gain unrealized loss bms repay million note maturity company repurchase certain longterm debt obligation interest rate range follow summarize debt redemption activity dollar million principal carry value debt redemption price loss debt redemptiona include acceleration debt issuance cost gain previously terminate interest rate swap contract relate fee interest payment million million million net amount receive interest rate swap contract december company separate revolve credit facility total billion syndicate lender include billion facility expire september july extendable annually year anniversary date consent lender january exist day billion facility expiring march replace new day billion facility expire january new threeyear billion facility expire january enter credit facility provide customary term condition financial covenant borrowing outstanding revolve credit facility december available financial guarantee provide form bank overdraft facility standby letter credit performance bond approximately billion december standby letter credit issue financial institution support guarantee obligation performance bond issue support range ongoing operating activity include sale product hospital foreign ministry health bond custom duty value add tax guarantee relate miscellaneous legal action note receivable december dollar million trade receivable chargeback cash discount bad debt allowance net trade receivables alliance receivables prepay refundable income taxis royaltie vat receivables nonus receivables sell nonrecourse basis million million million aggregate receivable pharmaceutical wholesaler represent total trade receivables december respectively change allowance bad debt chargeback cash discount follow year end december dollar million balance begin year provision utilization balance end year note inventory december dollar million finished good work process raw packaging material inventory inventory asset asset include inventory expect remain hand year period note property plant equipment lease december dollar million land building machinery equipment fixture construction progress gross property plant equipment accumulate depreciation property plant equipment united states europe rest world total depreciation expense million million million annual minimum rental commitment noncancelable operating lease primarily real estate motor vehicle approximately million year aggregate million operate lease expense approximately million million million sublease income capital lease obligation material period present note goodwill intangible asset december estimate dollar million useful life goodwill intangible asset license year develop technology right year capitalize software year iprd gross intangible asset accumulate amortization total intangible asset period adjustment include year end december reduce goodwill increase accumulate comprehensive loss million attribute goodwill prior acquisition foreign entity previously record correct local currency adjustment impact consolidate result operation material previously report balance sheet amortization expense intangible asset million million million future annual amortization expense intangible asset expect approximately million million million million million intangible asset impairment charge million million million million impairment charge record income net outlicensed asset obtain acquisition zymogenetics inc meet primary endpoint phase ii clinical study million iprd charge recognize attribute noncontrolle interest bms decline exercise option purchase fstar note accrue liability december dollar million rebate return employee compensation benefit research development dividend royalty brand prescription drug fee liability relate asset heldforsale litigation settlement restructure pension postretirement benefit accrue liability note equity common stock capital treasury stock excess accumulate par value comprehensive retain noncontrolle dollar share million share par value stock loss earning share cost interest balance january net earnings comprehensive lossincome cash dividend declaredc stock repurchase program stock compensation distribution balance december accounting change cumulative effecta adjust balance january net earnings comprehensive lossincome cash dividend declaredc stock repurchase program stock compensation variable interest entity distribution balance december accounting change cumulative effectb adjusted balance january net earnings comprehensive lossincome cash dividend declaredc stock repurchase program stock compensation adoption asu b distribution balance december cumulative effect result adoption asu b refer note accounting policy recently issue accounting standard additional information c cash dividend declare common share respectively bms stock repurchase program authorize board director allow repurchase open market private transaction include plan establish accordance rule b securities exchange act stock repurchase program expiration date suspend discontinue time treasury stock recognize cost reacquire share share issue treasury recognize utilize firstin firstout method bms repurchase billion common stock accelerate share repurchase agreement agreement fund combination debt cash component comprehensive lossincome follow year end december dollar million pretax tax tax pretax tax tax pretax tax tax derivative qualify cash flow hedge unrealize gainslosse reclassify net earningsa derivative qualify cash flow hedge pension postretirement benefit actuarial lossesgain amortizationb settlementsb pension postretirement benefit availableforsale security unrealize lossesgain realize gainslossesb availableforsale security foreign currency translation total comprehensive lossincome include cost product sell b include income net accumulate balance relate component comprehensive lossincome net taxis follow december dollar million derivative qualify cash flow hedge pension postretirement benefit availableforsale security foreign currency translation accumulate comprehensive loss note retirement benefit bms sponsor define benefit pension plan define contribution plan termination indemnity plan regular fulltime employee principal define benefit pension plan bristolmyers squibb retirement income plan plan cover employee represent approximately consolidated pension plan asset obligation future benefit relate service plan eliminate bms contribute minimum require erisa plan benefit base primarily participant year credit service final average compensation december plan asset consist primarily fixedincome security december bm announce plan fully terminate bristolmyer squibb retirement income plan plan pension obligation relate plan billion distribute combination lump sum payment eligible plan participant elect payment purchase group annuity contract athene annuity life company athene whollyowne insurance subsidiary athene holding ltd benefit obligation plan december determine plan termination basis assume portion eligible active defer vested participant elect lump sum payment remain obligation expect transfer athene include annuity purchase price premium plan sufficient asset satisfy transaction obligation transaction expect close quarter time company expect record total noncash pretax pension settlement charge approximately billion billion net periodic benefit costcredit define benefit pension plan include dollar million service cost benefit earn year interest cost project benefit obligation expect return plan asset amortization prior service credit amortization net actuarial loss settlement curtailment special termination benefit net periodic benefit costcredit pension settlement charge recognize determine annual lump sum payment exceed annual interest service cost certain pension plan include primary pension plan change define benefit pension plan obligation asset fund status amount recognize consolidated balance sheet follow dollar million benefit obligation begin year service costbenefit earn year interest cost settlement curtailment actuarial gainslosse benefit pay foreign currency benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution settlement benefit pay foreign currency fair value plan asset end year fund status assetsliabilitie recognize asset accrue liability pension liability fund status recognize accumulate comprehensive loss net actuarial loss prior service credit total accumulate benefit obligation define benefit pension plan billion billion december respectively additional information relate pension plan follow dollar million pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset actuarial assumption weightedaverage assumption determine define benefit pension plan obligation december follow discount rate rate compensation increase weightedaverage actuarial assumption determine define benefit pension plan net periodic benefit costcredit year end december follow discount rate expect longterm return plan asset rate compensation increase yield high quality corporate bond match duration benefit obligation determine discount rate citi pension discount curve develop discount rate plan expect return plan asset determine expect rate return calculate value asset refer marketrelated value approximate fair value plan asset december difference assume actual return amortize marketrelated value straightline basis threeyear period factor consider develop expect return plan asset include longterm historical return input external advisor individual asset class return forecast develop base market condition example priceearning level yield longterm growth expectation expect longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualize return pension plan follow year year year actuarial gain loss result change actuarial assumption change discount rate revise mortality rate difference assume actual experience difference actual expect return plan asset actuarial gain relate plan benefit obligation primarily result increase discount rate actuarial loss relate plan benefit obligation primarily result decrease discount rate gain loss amortize life expectancy plan participant plan year expect remain service period plan extent exceed high marketrelated value project benefit obligation respective plan result adopt asu refer note accounting policy recently issue accounting standard detail periodic benefit cost credit include income net service cost component include cost product sell research development marketing sell administrative expense postretirement benefit plan comprehensive medical group life benefit provide substantially retiree elect participate comprehensive medical group life plan less extent certain benefit nonus employee medical plan contributory contribution adjust periodically vary date retirement life insurance plan noncontributory plan asset consist principally equity fixedincome securities postretirement benefit plan obligation million million december respectively fair value plan asset million million december respectively weightedaverage discount rate determine benefit obligation december respectively net periodic benefit credit material plan asset fair value pension postretirement plan asset asset category december follow december december dollar million level level level total level level level total plan asset equity security equity fund fix income fund corporate debt security treasury agency security shortterm investment fund insurance contract cash cash equivalent plan asset subject leveling plan asset measure nav practical expedient equity fund venture capital limited partnership total plan asset measure nav practical expedient net plan asset investment valuation policy investment class follow level input utilize unadjusted quote price active market accessible measurement date identical asset liability fair value hierarchy provide high priority level input instrument include equity security equity fund fix income fund publicly trade national security exchange cash cash equivalent cash cash equivalent highly liquid investment original maturity month time purchase recognize cost approximate fair value pende trade sale purchase include cash cash equivalent final settlement level input utilize observable price similar instrument quote price identical similar instrument nonactive market observable input corroborate market datum substantially term asset liabilitie equity fund fix income fund shortterm investment fund classify level fair value hierarchy value nav share hold year end represent fair value corporate debt security treasury agency security classify level fair value hierarchy value utilize observable price similar instrument quote price identical similar instrument market active level unobservable input little market datum available insurance contract hold certain foreign pension plan carry contract value approximate estimate fair value base fair value underlie investment insurance company venture capital limited partnership investment typically redeemable distribution liquidation underlie asset significant unfunded commitment investment essentially liquidation expect occur end remain investment practical expedient redeemable weekly monthly basis investment strategy maximize return maintain appropriate level risk provide sufficient liquidity benefit obligation plan expense target allocation longduration fix income private equity adopt maintain principal define benefit pension plan bristolmyers squibb retirement income plan bms common stock represent plan asset december contribution estimate future benefit payment contribution pension plan million million million expect material estimate annual future benefit payment nonterminate plan include lump sum payment approximately million year subsequent year period saving plan principal define contribution plan bristolmyer squibb saving investment program contribution base employee contribution level company match expense attribute define contribution plan approximately million note employee stock benefit plan shareholder approve plan replace stock incentive plan plan provide million share authorize grant plus share outstanding award plan february expire forfeit cancel withhold satisfy tax withholding obligation december million share available award share issue treasury stock satisfy obligation plan executive officer key employee grant option purchase common stock market price date option grant option generally exercisable ratably year maximum term year plan provide grant stock appreciation right grantee surrender exercisable right receive common stock andor cash measure excess market price common stock option exercise price company grant stock option stock appreciation right restrict stock unit grant key employee subject restriction continuous employment generally vest occur ratably year period grant date stock unit right receive stock end specify vest period voting right market share unit grant executive vest condition continuous employment vest date payout factor share price award date payout factor share price vest date divide share price award date maximum share price payout factor calculate average closing price grant vest date trading day immediately precede grant vest date vest occur ratably year performance share unit grant executive year cycle grant target number unit subject adjustment number share issue performance share unit vest determine base achievement performance goal base company threeyear total shareholder return relative peer group company vest condition continuous employment occur anniversary grant date stockbase compensation expense award ultimately expect vest recognize vest period forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate information relate stockbase compensation benefit follow year end december dollar million restrict stock unit market share unit performance share unit total stockbase compensation expense income tax benefit stock option restrict stock unit market share unit performance share unit weight number weight number weight number weight number average average average average option exercise price nonveste grantdate nonveste grantdate nonveste grantdate share million outstanding share awards fair value award fair value award fair value balance january grant releasedexercised adjustment actual payout forfeitedcancele balance december vest expect vest restrict market performance dollar million stock unit share unit share unit unrecognize compensation cost expect weightedaverage period year compensation cost recognize amount million share datum weightedaverage grant date fair value share restrict stock unit market share unit performance share unit fair value award vest restricted stock unit market share unit performance share unit total intrinsic value stock option exercise fair value restrict stock unit market share unit performance share unit approximate close trading price bms common stock grant date adjust unit eligible accrue dividend addition fair value market share unit performance share unit consider probability satisfy payout factor total shareholder return respectively follow table summarize significant outstanding exercisable option december number weightedaverage weightedaverage aggregate outstanding exercisable remain contractual exercise price intrinsic value million life year share million option outstanding exercisable aggregate intrinsic value precede table represent total pretax intrinsic value base close stock price december note legal proceeding contingency company certain subsidiary involve lawsuit claim government investigation legal proceeding arise ordinary course business claim proceeding involve type party include government competitor customer supplier service provider licensee employee shareholder resolution matter develop long period time expectation change result new finding ruling appeal settlement arrangement company recognize accrual contingency probable liability incur loss reasonably estimate matter involve patent infringement antitrust security pricing sale marketing practice environmental commercial contractual right licensing obligation health safety matter consumer fraud employment matter product liability insurance coverage legal proceeding material company believe material describe company believe substantial defense matter assurance increase scope pende matter future lawsuit claim government investigation legal proceeding material note company unable assess outcome respective litigation able provide estimate range potential loss furthermore failure enforce patent right likely result substantial decrease respective product revenue generic competition intellectual property plavix australia previously disclose sanofi notify august genrx proprietary limited genrx obtain regulatory approval application clopidogrel bisulfate mg tablets australia genrx subsidiary apotex inc apotex change apotex august apotex file application federal court australia federal court seek revocation sanofis australian patent case nsd sanofi file counterclaims infringement seek injunction september federal court grant sanofis injunction subsidiary company subsequently add party proceeding february second company spirit pharmaceuticals pty ltd file revocation suit patent case consolidate apotex case trial occur april august federal court australia hold claim patent cover clopidogrel bisulfate hydrochloride hydrobromide taurocholate salt valid federal court hold process claim pharmaceutical composition claim claim direct clopidogrel pharmaceutically acceptable salt invalid company sanofi file notice appeal court federal court australia court appeal hold invalidity claim cover clopidogrel pharmaceutically acceptable salt process claim pharmaceutical composition claim stay federal court rule apotex file notice appeal appeal hold validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claim hearing appeal occur february september court hold claim patent invalid november company sanofi apply high court australia high court special leave appeal judgment court march high court deny company sanofis request hear appeal court decision case remand federal court proceeding relate damage seek apotex company apotex settle apotex case case dismiss australian government intervene matter seek maximum damage million aud million plus interest split company sanofi allege loss experience pay high price brand plavix period injunction place company sanofi dispute australian government entitle damage australian government claim pende trial conclude september company expect decision sprycel europe apotex actavis group ptc ehf generics uk limited mylan unnamed company file opposition epo seek revocation european patent patent cover dasatinib active ingredient sprycel january opposition division epo revoke patent company appeal epos decision epo board appeal february epo board appeal uphold opposition division decision revoke patent orphan drug exclusivity datum exclusivity sprycel eu expire november epo board appeal decision affect validity sprycel patent outside europe include different patent cover monohydrate form dasatinib use dasatinib treat cml additionally february epo board appeal reverse remand invalidity decision european patent claim use dasatinib treat cml epos opposition division revoke october december epos opposition division uphold validity patent direct use dasatinib treat cml expire company intend appropriate legal action protect sprycel generic approve certain eu market experience decline european revenue event generic dasatinib product enter market antipd antibody patent opposition litigation september danafarber cancer institute danafarber file complaint massachusetts federal court seek correct inventorship relate patent direct method treat cancer pd pdl antibodie specifically danafarber seeking add scientist inventor patent october pfizer allow intervene case allege scientist identify danafarber employ company eventually acquire pfizer relevant period february company settle lawsuit pfizer bench trial lawsuit danafarber begin february decision expect eliquis patent litigation twentyfive generic company send company paragraphiv certification letter inform company file anda seek approval generic version eliquis result eliquis patent list fda orange book challenge composition matter patent claim apixaban specifically formulation patent april company partner pfizer initiate patent lawsuit hatchwaxman act generic filer federal district court delaware west virginia august patent trademark office grant patent term restoration composition matter patent restore term eliquis composition matter patent company basis project loe february november company settle lawsuit number anda filer december settlement affect company project loe eliquis pricing sale promotional practice litigation plavix state attorney general lawsuit company certain affiliate sanofi defendant consumer protection andor false advertising action bring state relate sale promotion plavix product liability litigation company party product liability lawsuit plaintiff case seek damage relief ground allege personal injury economic loss previously disclose addition lawsuit company face unfiled claim involve product byetta amylin subsidiary company lilly codefendant product liability litigation relate byetta date separate lawsuit pende behalf approximately active plaintiff include pende settlement include injury plaintiff claim spouse andor beneficiary court majority case bring individual allege personal injury sustain byetta primarily pancreatic cancer case claim alleged wrongful death majority case pende federal court san diego mdl coordinated proceeding california superior court los angeles jccp november defendant motion summary judgment base federal preemption grant mdl jccp november ninth circuit reverse mdl summary judgment order remand case mdl november california court appeal reverse state court dismissal state court case remand jccp proceeding amylin product liability insurance cover substantial number claim involve byetta additional liability amylin respect byetta expect share company astrazeneca abilify company otsuka codefendant product liability litigation relate abilify plaintiff allege abilify cause engage compulsive gambling impulse control disorder case file state federal court additional case pende canada judicial panel multidistrict litigation consolidated federal court case pretrial purpose district court northern district florida february company otsuka enter master settlement agreement establish propose settlement program resolve abilify compulsivity claim file january mdl state court include california new jersey eliquis company pfizer codefendant product liability litigation relate eliquis plaintiff assert claim include claim wrongful death result bleed allege cause use eliquis january claim remain pende mdl district court southern district new york case remain pende state court remain pende canada case dismiss prejudice mdl claim plaintiff appeal second circuit court appeal company expect decision onglyza company astrazeneca codefendant product liability litigation relate onglyza plaintiff assert claim include claim wrongful death result heart failure cardiovascular injury allege cause use onglyza january claim pende state federal court behalf approximately individual allege ingest product suffer injury significant majority claim pende federal court february judicial panel multidistrict litigation order federal case transfer mdl district court eastern district kentucky company global diabete business divestiture company sell onglyza astrazeneca february potential liability respect onglyza expect share astrazeneca shareholder derivative litigation december shareholder derivative lawsuit file new york state court certain officer director company plaintiff allege thing breach fiduciary duty surround company previously disclose october civil settlement sec allege fcpa violation china company agree payment approximately million disgorgement penalty interest october lawsuit dismiss company receive notice appeal dismiss lawsuit oral argument appeal dismissal schedule february security litigation february separate putative class action complaint file district northern district california district court southern district new york company company chief executive officer giovanni caforio company chief financial officer charle bancroft certain current executive company case california voluntarily dismiss remain complaint allege violation security law company disclosure relate checkmate clinical trial lung cancer fully brief motion dismiss pende court company intend defend vigorously litigation litigation acquisition celgene litigation february complaint file celgene shareholder district court district delaware district court district new jersey district court southern district new york court chancery state delaware seek enjoin company propose acquisition celgene complaint action defendant celgene member celgene board director complaint company burgundy merger sub inc whollyowne subsidiary company form solely purpose complete pende acquisition celgene merge celgene completion acquisition defendant complaint name company defendant style putative class action plaintiff allege violation federal security law breach fiduciary duty connection acquisition celgene company separately tenth complaint style putative class action file court chancery state delaware behalf company shareholder naming member company board director defendant complaint allege member company board director breach fiduciary duty company shareholder fail disclose material information pende acquisition company burgundy merger sub celgene intend defend vigorously lawsuit acquisition flexus litigation february company acquire flexus include right ido inhibitor september incyte corporation incyte sue flexus flexus founder flexus defendant superior court state delaware initial subsequent amend complaint incyte allege claim flexus defendant misappropriation trade secret relate research development incyte ido inhibitor november follow ahalf week trial trade secret jury superior court delaware return defense verdict behalf flexus defendant incyte appeal decision average wholesale price litigation company defendant qui tam whistleblower lawsuit district court eastern district pennsylvania government decline intervene complaint allege company inaccurately report average manufacturer price center medicare medicaid services lower owe similar claim file company court deny company motion dismiss november government investigation like pharmaceutical company company certain subsidiary subject extensive regulation national state local government agency country bms operate result company time time subject governmental inquiry investigation possible criminal charge substantial fine andor civil penalty result government investigation environmental proceeding previously report company party environmental proceeding matter responsible state federal foreign law include cercla certain cost investigate andor remediate contamination result past industrial activity company current site waste disposal reprocess facility operate party cercla matter respect cercla matter company responsible state federal foreign law company typically estimate potential cost base information obtain environmental protection agency counterpart state foreign agency andor study prepare independent consultant include total estimate cost site expect costshare potentially responsible party company accrue liability probable reasonably estimable company estimate share future cost site million december represent sum good estimate good estimate reasonably estimate minimal probable range cost take account potential recovery party include estimate cost additional probable loss associate previously disclose north brunswick township high school remediation site note subsequent event january bms announce company enter definitive merger agreement bms acquire celgene term agreement merger complete celgene shareholder receive share bms common stock cash share celgene common stock hold celgene shareholder receive tradeable contingent value right share celgene represent right receive cash subject achievement future regulatory milestone base closing price share bms common stock january recent trading day prior date announcement merger consideration represent approximately billion consideration receive celgene stockholder fluctuate change price share bms common stock bms expect fund transaction combination exist cash new debt bms expect enter accelerate share repurchase program approximately billion subject closing transaction market condition board director approval company expect transaction close end quarter subject approval bristolmyers squibb celgene shareholder satisfaction customary closing condition regulatory approval note select quarterly financial datum unaudite dollar million share datum quarter second quarter quarter fourth quarter year total revenue gross margin net earning net earningsloss attributable noncontrolle interest bms earning share basica earning share diluteda cash dividend declare common share cash cash equivalent marketable securitiesb total asset longterm debtc equity dollar million share datum quarter second quarter quarter fourth quarter year total revenue gross margin net earning net earningsloss attributable noncontrolle interest bms earningsloss share basica earningsloss share diluteda cash dividend declare common share cash cash equivalent marketable securitiesb total asset longterm debtc equity earning share quarter add amount year period compute discrete basis b marketable security include current noncurrent asset c longterm debt include current portion follow specify item affect comparability result second fourth dollar million quarter quarter quarter quarter year cost product solda marketing sell administrative license asset acquisition charge site exit cost research development lossgain equity investment provision restructure litigation settlement divestiture gain royalty license income pension postretirement intangible asset impairment income net increasedecrease pretax income income taxis item income taxis attribute tax reform income taxis increasedecrease net earning second fourth dollar million quarter quarter quarter quarter year cost product solda marketing sell administrative license asset acquisition charge iprd impairment site exit cost research development provision restructure litigation settlement divestiture gain royalty license income pension postretirement loss debt redemption income net increasedecrease pretax income income taxis item income taxis attribute tax reform income taxis increasedecrease net earning noncontrolle interest increasedecrease net earning attributable bms specify item cost product sell accelerate depreciation asset impairment shutdown cost report independent register public accounting firm shareholder board director bristolmyers squibb company opinion financial statement audit accompany consolidated balance sheet bristolmyer squibb company subsidiary company december relate consolidated statement earning comprehensive income cash flow year period end december relate note collectively refer financial statement opinion financial statement present fairly material respect financial position company december result operation cash flow year period end december conformity accounting principle generally accept united states america audit accordance standard public company accounting oversight board united states pcaob company internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion company internal control financial reporting basis opinion financial statement responsibility company management responsibility express opinion company financial statement base audits public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audit obtain reasonable assurance financial statement free material misstatement error fraud audits include perform procedure assess risk material misstatement financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation financial statement believe audits provide reasonable basis opinion deloitte touche llp parsippany new jersey february serve company auditor item change disagreement accountant account financial disclosure item control procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure control procedure define exchange act rule ae de end period cover base evaluation management conclude december disclosure control procedure effective management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting define exchange act rule af supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include report form k issue report effectiveness company internal control financial reporting december include change internal control financial reporting change company internal control financial reporting quarter end december materially affect reasonable likely materially affect company internal control financial reporting item b information february company amendment registration statement form company pende acquisition celgene company disclose starboard value lp send notice nomination director company board director company inform starboard value review connection delivery notice starboard value request meet company management pende discussion notice meeting keep confidential company management subsequently meet starboard value multiple occasion vote potential change company board director come annual meeting shareholder date set time file company shareholder expect vote propose acquisition celgene april report independent register public accounting firm shareholder board director bristolmyers squibb company opinion internal control financial reporting audit internal control financial reporting bristolmyer squibb company subsidiary company december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue coso audit accordance standard public company accounting oversight board united states pcaob consolidate financial statement year end december company report date february express unqualified opinion consolidated financial statement basis opinion company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audit accordance standard pcaob standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp parsippany new jersey february iii item director executive officer registrant reference proxy statement respect director incorporate reference hereof response information require item b information require item respect executive officer include ia reliance general instruction g instruction item b regulation sk incorporate reference hereof response information require item item executive compensation reference proxy statement respect executive compensation incorporate reference hereof response information require item item security ownership certain beneficial owner management relate stockholder matter reference proxy statement respect security ownership certain beneficial owner management incorporate reference hereof response information require item item certain relationship relate transaction reference proxy statement respect certain relationship relate transaction incorporate reference hereof response information require item item auditor fee reference proxy statement respect auditor fee incorporate reference hereof response information require item iv item